US20230381340A1 - Aav-mediated delivery of atp1a3 genes to central nervous system - Google Patents
Aav-mediated delivery of atp1a3 genes to central nervous system Download PDFInfo
- Publication number
- US20230381340A1 US20230381340A1 US18/449,346 US202318449346A US2023381340A1 US 20230381340 A1 US20230381340 A1 US 20230381340A1 US 202318449346 A US202318449346 A US 202318449346A US 2023381340 A1 US2023381340 A1 US 2023381340A1
- Authority
- US
- United States
- Prior art keywords
- atp1a3
- sequence
- aav9
- promoter
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 title abstract description 45
- 230000001404 mediated effect Effects 0.000 title 1
- 101000753178 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-3 Proteins 0.000 claims abstract description 175
- 102100021952 Sodium/potassium-transporting ATPase subunit alpha-3 Human genes 0.000 claims abstract description 172
- 239000013607 AAV vector Substances 0.000 claims abstract description 65
- 239000013598 vector Substances 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 50
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 34
- 108020004414 DNA Proteins 0.000 claims abstract description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 20
- 101150021723 Atp1a3 gene Proteins 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 230000014509 gene expression Effects 0.000 claims description 44
- 210000001638 cerebellum Anatomy 0.000 claims description 41
- 208000005875 Alternating hemiplegia of childhood Diseases 0.000 claims description 33
- 210000002569 neuron Anatomy 0.000 claims description 27
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 23
- 241000282414 Homo sapiens Species 0.000 claims description 22
- 210000000133 brain stem Anatomy 0.000 claims description 21
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 238000013519 translation Methods 0.000 claims description 15
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 14
- 238000007913 intrathecal administration Methods 0.000 claims description 13
- 230000008488 polyadenylation Effects 0.000 claims description 11
- 241000702421 Dependoparvovirus Species 0.000 claims description 9
- 210000001320 hippocampus Anatomy 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 210000003703 cisterna magna Anatomy 0.000 claims description 5
- 230000007658 neurological function Effects 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 4
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000000185 intracerebroventricular administration Methods 0.000 claims description 4
- 210000000278 spinal cord Anatomy 0.000 claims description 4
- 210000003710 cerebral cortex Anatomy 0.000 claims description 3
- 210000002451 diencephalon Anatomy 0.000 claims description 2
- 210000001587 telencephalon Anatomy 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 210000004289 cerebral ventricle Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 32
- 230000009261 transgenic effect Effects 0.000 abstract description 22
- 241000124008 Mammalia Species 0.000 abstract description 21
- 230000035772 mutation Effects 0.000 abstract description 11
- 241000700605 Viruses Species 0.000 abstract description 10
- 208000012902 Nervous system disease Diseases 0.000 abstract description 9
- 230000002463 transducing effect Effects 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 59
- 241000699666 Mus <mouse, genus> Species 0.000 description 52
- 238000010186 staining Methods 0.000 description 49
- 210000000449 purkinje cell Anatomy 0.000 description 41
- 241000649044 Adeno-associated virus 9 Species 0.000 description 39
- 210000004556 brain Anatomy 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 23
- 239000000427 antigen Substances 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 21
- 108060001061 calbindin Proteins 0.000 description 20
- 210000005110 dorsal hippocampus Anatomy 0.000 description 20
- 108700019146 Transgenes Proteins 0.000 description 19
- 102000014823 calbindin Human genes 0.000 description 19
- 101150014889 Gad1 gene Proteins 0.000 description 17
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 17
- 230000000946 synaptic effect Effects 0.000 description 15
- 230000014616 translation Effects 0.000 description 15
- 238000001415 gene therapy Methods 0.000 description 13
- 101100217449 Mus musculus Atp1a3 gene Proteins 0.000 description 12
- 238000010361 transduction Methods 0.000 description 11
- 230000026683 transduction Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 238000002372 labelling Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 210000000234 capsid Anatomy 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 108091029865 Exogenous DNA Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 230000001936 parietal effect Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 208000014094 Dystonic disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004227 basal ganglia Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000010118 dystonia Diseases 0.000 description 4
- 210000004055 fourth ventricle Anatomy 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 206010003591 Ataxia Diseases 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 101710185809 Sodium/potassium-transporting ATPase subunit alpha-3 Proteins 0.000 description 3
- 238000013308 adult mouse model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 230000004777 loss-of-function mutation Effects 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000002975 pon Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001103 thalamus Anatomy 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 208000020100 Auditory neuropathy spectrum disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 208000007192 Childhood Schizophrenia Diseases 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 102000004648 Distal-less homeobox proteins Human genes 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 101100217448 Homo sapiens ATP1A3 gene Proteins 0.000 description 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 208000000060 Migraine with aura Diseases 0.000 description 2
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 208000018688 Rapid-onset dystonia-parkinsonism Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000002982 auditory neuropathy Diseases 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000003591 cerebellar nuclei Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010067039 familial hemiplegic migraine Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003371 gabaergic effect Effects 0.000 description 2
- 102000053319 human ATP1A3 Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000000337 motor cortex Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 101150116038 AEP2 gene Proteins 0.000 description 1
- 101150027183 ATP1A1 gene Proteins 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102100021851 Calbindin Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000039077 Copula Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010066054 Dysmorphism Diseases 0.000 description 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
- 241001492222 Epicoccum Species 0.000 description 1
- 206010061159 Foot deformity Diseases 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 1
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 1
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 1
- 101000701334 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-1 Proteins 0.000 description 1
- 101000575685 Homo sapiens Synembryn-B Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 101150117564 ITR2 gene Proteins 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000258952 Lingula Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100135809 Mus musculus Pcp2 gene Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 102100037591 Neuroserpin Human genes 0.000 description 1
- 241000167610 Nodulus Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000001675 Parvalbumin Human genes 0.000 description 1
- 108060005874 Parvalbumin Proteins 0.000 description 1
- 102000019204 Progranulins Human genes 0.000 description 1
- 108010012809 Progranulins Proteins 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101100217451 Rattus norvegicus Atp1a3 gene Proteins 0.000 description 1
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 1
- -1 SIRT-2 Proteins 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 102100030458 Sodium/potassium-transporting ATPase subunit alpha-1 Human genes 0.000 description 1
- 208000023944 Sudden Unexpected Death in Epilepsy Diseases 0.000 description 1
- 206010063894 Sudden unexplained death in epilepsy Diseases 0.000 description 1
- 102100026014 Synembryn-B Human genes 0.000 description 1
- 208000008206 Talipes Cavus Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000001926 inhibitory interneuron Anatomy 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 108010080874 neuroserpin Proteins 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 231100000847 severe hepatotoxicity Toxicity 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to the delivery and expression of ATP1A3 genes in the central nervous system.
- Alternating Hemiplegia of Childhood is a serious and rare neurodevelopmental disorder, affecting approximately 1 in 1,000,000 children.
- AHC is caused by de novo loss-of-function mutations in the ATP1A3 gene (Heinzen et al., 2012; Rosewich et al., 2012).
- the gene encodes the ⁇ 3 subunit of the Na+, K+ ATPase, one of two pumps that establish and maintain electrochemical gradients required for the propagation of action potentials in neurons.
- AHC-associated mutations do not affect expression of ATP1A3 gene or levels of its protein, but significantly reduce ⁇ 3 protein functionality (Heinzen et al., 2012; Li et al., 2015).
- ATP1A3 gene is expressed in the central nervous system (CNS) and heart of all mammals studied. Brain expression of ATP1A3 is enriched in high frequency GABAergic interneurons of the cerebellum, pons, basal ganglia, thalamus, cortex and hippocampus (B ⁇ ttger et al., 2011; Hieber et al., 1991; McGrail et al., 1991; Pietrini et al., 1992; Richards et al., 2007).
- Clinical symptoms of cerebellar, hippocampal, basal ganglia, and motor cortex dysfunction largely correlate with persistent symptoms of AHC. In line with clinical symptoms, brains of AHC patients show progressive frontal dominant cerebral, severe hippocampal, and diffuse cerebellar atrophy (Sasaki et al., 2017). Paroxysmal symptoms of AHC likely originate in Purkinje cells and spread through the afferent networks of the cerebellum by spreading depolarization (“spreading depression”).
- AHC symptoms appear before 18 months of age, and often shortly after birth. AHC causes severe morbidity and increased mortality. Patients often suffer severe neurodevelopmental impairments, episodes of paralysis, severe dystonia, ataxia, swallowing problems, epilepsy, status epilepticus, sudden unexpected death, and episodes of developmental regression (Mikati et al., 2000; Panagiotakaki et al., 2015). Currently, there is no effective on-target treatment, although certain off-target drugs like Flunarizine have been reported to have some limited effect on certain symptoms.
- mutations in ATP1A3 gene are associated with at least eight other distinct, but clinically overlapping neurological disorders (Dard et al., 2015; de Carvalho Aguiar et al., 2004; Demos et al., 2014; Heinzen et al., 2014; Paciorkowski et al., 2015; Smedemark-Margulies et al., 2016; Sweadner et al., 2016; Sweney et al., 2015; Yano et al., 2017).
- the clinical symptoms of these diseases partly intersect and range from mild to severe.
- transgenic vector for transducing cells of the central nervous system of a mammal and transgenically expressing a protein in the central nervous system of the mammal.
- the transgenic vector comprises a virus-derived vector, a nucleic acid sequence encoding the protein, and an endogenous ATP1A3 promoter (P ATP1A3 ) sequence.
- compositions comprising a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a ATP1A3 (sodium/potassium-transporting ATPase subunit alpha-3) protein, in a form compatible with administration into the central nervous system.
- AAV adeno-associated virus
- Another aspect of the invention relates to a method for treating a subject having a neurological disorder associated with mutations in the ATP1A3 gene.
- the method comprises administering into the central nervous system (CNS) of the subject a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a ATP1A3 protein, thereby restoring some degree of neurological function in said subject.
- CNS central nervous system
- AAV adeno-associated virus
- Another aspect of the invention relates to a method for delivering to the central nervous system of a mammal, a ATP1A3 DNA that is expressed in a cell of the central nervous system.
- the method comprises administering into the central nervous system of the mammalian a recombinant AAV vector comprising a nucleic acid sequence encoding a ATP1A3 protein, wherein said vector transduces the cell.
- FIG. 1 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse cerebellum. All images were acquired with the same microscope settings (exposure time, image dynamic range).
- FIG. 2 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse cerebellum, as a zoomed image.
- FIG. 3 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse brain at dorsal hippocampus level. All images were acquired with the same microscope settings (exposure time, image dynamic range).
- FIG. 4 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse brain at dorsal hippocampus level, as a zoomed image.
- FIG. 5 depicts ATP1A3 (Millipore #06-172-1) staining in the dorsal hippocampus, as zoomed image.
- FIG. 6 depicts ATP1A3 (Millipore #06-172-1) staining in the parietal cortex, as a zoomed image.
- FIG. 7 depicts Calbindin (Synaptic Systems #214006) staining in a mouse cerebellum.
- FIG. 8 depicts Calbindin (Synaptic Systems #214006) staining in a mouse cerebellum, as a zoomed image.
- FIG. 9 depicts GAD67 (Synaptic Systems #198 006) staining in a mouse brain at dorsal hippocampus level.
- FIG. 10 depicts GAD67 (Synaptic Systems #198 006) staining in mouse brain at dorsal hippocampus level, pH8 antigen retrieval protocol, as a zoomed image over the dorsal hippocampus.
- FIG. 11 depicts GAD67 (Millipore #MAB5406) staining in a mouse brain at dorsal hippocampus level.
- FIG. 12 depicts: GAD67 (Millipore #MAB5406) staining in mouse brain at dorsal hippocampus level, pH8 antigen retrieval protocol.
- Zoomed image over the dorsal hippocampus showing good detection of GABAergic neurons in the hippocampus and in the cortex.
- FIG. 13 depicts mCherry staining in a mouse cerebellum.
- FIG. 14 depicts the mouse cerebellum anatomy.
- FIG. 15 depicts mCherry staining in mouse cerebellum with pH8 antigen retrieval condition, as zoomed images.
- FIG. 16 depicts mCherry staining in mouse cerebellum with pH8 antigen retrieval condition, as zoomed images.
- FIG. 17 depicts histograms of the mean intensity of ATP1A3 in the 4 experimental groups. Histograms are well superposed.
- FIG. 18 depicts histograms of the mean intensity of ATP1A3 in the 4 experimental groups with the gate for highest fluorescence levels.
- FIG. 19 depicts an example of Purkinje cell detection. Contours of detected cells are shown.
- FIG. 20 depicts an example of Purkinje cell detection showing cells with higher ATP1A3 levels. Contours of detected cells are shown in dark shading, and cells in gate are shown in light shading.
- FIG. 21 depicts an example of Purkinje cell detection showing cells with higher ATP1A3 levels. Contours of detected cells are shown in dark shading, and cells in gate are shown in light shading.
- FIG. 22 depicts graphical representations of mean ATP1A3 intensity in Purkinje Neurons and percentage of Purkinje neurons with high ATP1A3 intensity.
- the left graft shows mean intensity in Purkinje Neurons, and the right graph shows the percentage of Purkinje neurons with High ATP1A3 intensity.
- FIG. 23 depicts graphical representations of mean ATP1A3 intensity in cerebellar cells other than Purkinje neurons.
- FIG. 24 depicts a histogram of the mean intensity of mCherry in the mCherry group and animals from ATP1A3 infected groups, with gate for highest fluorescence levels.
- FIG. 25 depicts an example of Purkinje cell detection showing cells with higher mCherry levels (cells in Gate named Highest). Contours of detected cells are shown in black, and cells in gate are shown in dark shading.
- FIG. 26 depicts graphical representations of mean mCherry intensity in Purkinje Neurons and the percentage of Purkinje neurons with high mCherry intensity.
- the left graft shows the mean intensity in Purkinje Neurons.
- the right graph shows the percentage of Purkinje neurons with High mCherry intensity.
- FIG. 27 depicts graphical representations of mean mCherry intensity in cerebellar cells other than Purkinje neuron.
- FIG. 28 depicts counts of mCherry positive cells in mCherry infected brainstems.
- FIG. 29 depicts an example of cells with higher ATP1A3.
- FIG. 30 depicts quantification of ATP1A3 immunofluorescence.
- the left graft shows ATP1A3 immunofluorescence at the surrounding of all detected cells.
- the middle graft shows the percentage of cells detected as higher expressing ATP1A3 after gating.
- the right graft shows mean fluorescence in cells in highest ATP1A3 gate.
- transgenic vector for transducing cells of the central nervous system of a mammal and transgenically expressing a protein in the central nervous system of the mammal.
- the transgenic vector comprises a virus-derived vector, a nucleic acid sequence encoding the protein, and an endogenous ATP1A3 promoter (P ATP1A3 ) sequence.
- Suitable viral vectors include those neurotrophic viral vectors, including, but not limited to, adeno-associated viral vectors (AAV), herpes simplex viral vectors and lentiviral vectors. More discussions about the herpes simplex viral vectors may be found in U.S. Pat. No. 5,672,344, which is incorporated herein by reference in its entirety.
- AAV adeno-associated viral vectors
- herpes simplex viral vectors More discussions about the herpes simplex viral vectors may be found in U.S. Pat. No. 5,672,344, which is incorporated herein by reference in its entirety.
- the transgenic vector also comprises a nucleic acid sequence encoding a protein (DNA encoding the protein, e.g., cDNA of protein), the transgene.
- the transgene encodes a biologically active protein which is transgenically expressed in the central nervous system of a mammal.
- the transgene may be ATP1A3 (sodium/potassium-transporting ATPase subunit alpha-3).
- the transgenes may also be insulin growth factor-1 (IGF-1), calbindin D28, parvalbumin, HIF1-alpha, SIRT-2, VEGF, SMN-1, SMN-2, CNTF (Ciliary neurotrophic factor), sonic hedgehog (shh), erythropoietin (EPO), lysyl oxidase (LOX), progranulin, prolactin, ghrelin, neuroserpin, or placenta lactogen.
- the protein-coding nucleic acid may be an DNA sequence, an “exogenous DNA” that is exogenous to both AAV and to the target cell.
- the DNA may be synthetic DNA, complementary DNA, genomic DNA, or a combination thereof.
- the DNA may be of any sequence or length, provided that it may be incorporated into the vector and delivered to target cells. Typically, because of the packaging limitations of AAV, the exogenous DNA will have a length of up to 4,400 bases.
- transgenic vector More than one transgene can be delivered by the transgenic vector, e.g., via more than one virus-derived vector.
- the transgenic vector comprises multiple AAV vectors and each AAV vector comprises a transgene operably linked to a promoter.
- the protein-coding nucleic acid is operably linked to a promoter sequence to enable the expression of the trangene from a single AAV vector.
- the protein-coding nucleic acid shall be operably linked to a promoter sequence so that when the promoter is activated, the coding sequence is transcribed.
- the protein-coding nucleic acid is operably linked if the linkage does not cause an error in the reading of the downstream sequence. To be “operably linked,” it is not necessary that two sequences be immediately adjacent to one another.
- the promoter sequence drives transcription of the transgene and defines the cellular specificity of its expression.
- the promoter sequence is an endogenous ATP1A3 promoter (P ATP1A3 ) sequence.
- the P ATP1A3 promoter comprises a mouse promoter sequence, SEQ ID NO: 1.
- the P ATP1A3 promoter comprises a homologous human sequence.
- the transgenic vector may further comprise one or more nucleic acid regulatory sequence, linked directly or indirectly to the protein-coding nucleic acid sequence.
- a promoter specific to the gene may be incorporated into the transgenic vector.
- the nucleic acid regulatory sequence comprises a sequence to regulate ribosome binding and/or translation efficiency of the ATP1A3 gene.
- the nucleic acid regulatory sequence comprises a 3′-UTR sequence that contains a polyadenylation sequence.
- the transgenic vector comprises an AAV vector (e.g., a recombinant AAV vector), a P ATP1A3 promoter, and a mCherry transgene.
- AAV vector e.g., a recombinant AAV vector
- P ATP1A3 promoter e.g., a P ATP1A3 promoter
- mCherry transgene e.g., a recombinant AAV vector
- the transgenic vector comprises AAV9 vector (e.g., recombinant AAV9 vector), a P ATP1A3 promoter, a mCherry transgene, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence.
- AAV9 vector e.g., recombinant AAV9 vector
- P ATP1A3 promoter e.g., recombinant AAV9 vector
- a mCherry transgene e.g., a sequence to regulate ribosome binding and/or translation efficiency
- a 3′-UTR sequence that contains a polyadenylation sequence.
- the transgenic vector comprises SEQ ID NO: 2.
- the transgenic vector comprises an AAV vector (e.g., a recombinant AAV vector), a P ATP1A3 promoter, and a ATP1A3 transgene.
- AAV vector e.g., a recombinant AAV vector
- P ATP1A3 promoter e.g., a P ATP1A3 promoter
- ATP1A3 transgene e.g., ATP1A3 transgene
- the transgenic vector comprises AAV9 vector (e.g., recombinant AAV9 vector), a P ATP1A3 promoter, a ATP1A3 transgene, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence.
- AAV9 vector e.g., recombinant AAV9 vector
- P ATP1A3 promoter e.g., recombinant AAV9 vector
- a ATP1A3 transgene e.g., a sequence to regulate ribosome binding and/or translation efficiency
- a 3′-UTR sequence that contains a polyadenylation sequence.
- the transgenic vector comprises SEQ ID NO: 3.
- compositions and methods for intracisternal or intrathecal administration of recombinant AAV comprising a gene that affects neurological function are also disclosed herein.
- the embodiments of the invention illustrate that some neurological disorders associated with loss-of-function mutations of ATP1A3 genes (e.g., alternating hemiplegia of childhood, “AHC”) can be better addressed with a more targeted delivery of the gene therapy.
- AHC alternating hemiplegia of childhood
- the phenotype of an AHC mouse model has been rescued by transgenesis.
- Inclusion of extra-chromosomal copies of ATP1A3 by transgenesis has been shown to be sufficient to increase Na+, K+ ATPase activity in the brain and confer significant phenotypic improvements compared to non-transgenic mice with the same AHC associated mutation.
- compositions comprising a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a ATP1A3 (sodium/potassium-transporting ATPase subunit alpha-3) protein, in a form compatible with administration into the central nervous system.
- AAV adeno-associated virus
- the composition contains an adeno-associated virus (AAV) vector.
- AAV adeno-associated virus
- the vector may be a derivative of the adeno-associated virus, into which exogenous DNA is introduced.
- AAV vector is used herein as a carrier to deliver ATP1A3 cDNA.
- AAV is a replication-defective, non-enveloped parvovirus, present in humans and some other primate species but not associated with any pathology.
- Recombinant AAV vectors are used for the development of human therapeutics because they can infect quiescent non-dividing cells (like neurons), mediate long-term gene expression, and, unlike retroviruses, persist in an extrachromosomal state without integrating into the genome of the host cell. Since AAV does not integrate into the host genome, the use of this viral vector mitigates risks associated with unintended off-target effects of genomic editing (Schaefer et al., 2017; Zhang et al., 2015).
- AAV vectors are derived from single-stranded (ss) DNA parvoviruses that are nonpathogenic for mammals. Briefly, recombinant AAV-based vectors have two open reading frames, the rep and cap viral genes that account for 96% of the viral genome removed, leaving the two flanking 145-basepair (bp) inverted terminal repeats (ITRs), which are used to initiate viral DNA replication, packaging and integration. These ITRs allow for synthesis of the complementary DNA strand. Rep and Cap are translated to produce multiple distinct proteins. When constructing an AAV transfer plasmid, the transgene is placed between the two ITRs, and Rep and Cap are supplied in trans. In the absence of helper virus, wild-type AAV is typically maintained episomally.
- a single AAV particle can accommodate up to 5 kb of ssDNA, therefore leaving about 4.5 kb for a transgene and regulatory elements, which is typically sufficient.
- trans-splicing systems as described, for example, in U.S. Pat. No. 6,544,785, which is incorporated herein by reference in its entirety, may nearly double this limit.
- small (4.8 kb) ssDNA AAV genome having ITR sequences flanking the insert are of ITR2 serotype.
- AAV vector of any serotype can be used.
- Particular useful serotypes are those that are particularly suitable for nervous cells, e.g., AAV1, AAV2, AAV4, AAV5, AAV8, AAV9, AAV-PHP.B, or AAVrh10.
- Several of these AAV serotypes have been utilized in clinical Phase I and II studies for diseases that require CNS delivery (reviewed in (Naso et al., 2017)).
- Initial testing of AAV2-based RPE65 delivery has been done in canine culture.
- Other serotype besides those listed herein can be used.
- pseudotyped AAV vectors may also be used herein.
- Pseudotyped AAV vectors are those which contain the genome of one AAV serotype in the capsid of a second AAV serotype; for example, an AAV vector that contains the AAV2 capsid and the AAV1 genome or an AAV vector that contains the AAV5 capsid and the AAV 2 genome.
- AAV-based gene therapy targeted to cells of the CNS has been described in U.S. Pat. Nos. 6,180,613 and 6,503,888, which are incorporated by reference in their entirety.
- Exemplary AAV vectors are recombinant AAV vectors encoding human protein.
- the AAV vector is AAV9 vector.
- AAV9 vector is used to deliver a rescue gene to the CNS neurons (e.g., in a mammal, such as mouse, primate, human).
- Cell-specificity of AAV infection is determined by the capsid serotype.
- AAV serotype 9 (AAV9) has natural tropism for neurons and was successfully applied to rescue adult mouse models of diseases such as mucopolysaccharidosis (Fu et al., 2010; Hinderer et al., 2016; Watson et al., 2006) and diabetic neuropathy (Homs et al., 2014).
- AAV9 Injection of AAV9 into cerebrospinal fluid has been highly efficient in targeting the CNS in adult mice (Bey et al., 2017; Fu et al., 2010) and pigs (Federici et al., 2012).
- AAV9 vectors showed preferentially higher selectivity of neuronal transduction in adult non-human primate compared to other serotypes (El-Shamayleh et al., 2017).
- the gene therapy is conducted in various mouse models (that phenocopy many clinical symptoms of AHC) by injecting ATP1A3 DNA-carrying AAV9 capsids into cerebrospinal fluid (via injection into cisterna magna), using a similar method used to rescue adult mouse models of Mucopolysaccharidosis (Hinderer et al., 2016; Watson et al., 2006; DiRosario et al., 2010) and diabetic neuropathy (J. Homs et al., 2014).
- the ATP1A3-coding nucleic acid may be a DNA sequence, an “exogenous DNA” that is exogenous to both AAV and to the target cell.
- DNA delivered to that subject may be considered exogenous even though it is identical to a gene native to that subject's species, provided it differs in the regulatory or coding region from the cognate gene of the subject to whom it is delivered, and therefore encodes a different gene product or is expressed to a different degree and/or in different cells, under at least some conditions.
- the DNA may be synthetic DNA, complementary DNA, genomic DNA, or a combination thereof.
- the DNA may be of any sequence or length, provided that it may be incorporated into the vector and delivered to target cells.
- the exogenous DNA will have a length of about 10-5,000 bases, e.g., 100 to 4,000 bases.
- the size of a typical ATP1A3 cDNA ( ⁇ 3 kb) fits within the carrying capacity of AAV vectors (4.4 kb).
- a mouse ATP1A3 cDNA sequence is used in ATP1A3-AAV9 vector for gene therapy used in mouse for compatibility.
- a sequence of the most common transcript isoform of mouse ATP1A3 gene NCBI reference sequence NM_001290469.1, may be used.
- only the ORF portion of the mRNA is included: from ATG start to TGA stop codons (including the latter).
- a human ATP1A3 cDNA sequence is used in ATP1A3-AAV9 vector for gene therapy used in human for compatibility.
- a sequence of the most abundant transcript of human ATP1A3 gene NCBI reference sequence NM_152296.4 (SEQ ID NO: 6), may be used.
- no tags are added to its coding sequence in order not to interfere with transgenic ATP1A3 protein translation, folding, transport and function.
- the composition further comprises one or more nucleic acid regulatory sequences, linked directly or indirectly to the ATP1A3-coding nucleic acid sequence.
- the nucleic acid regulatory sequence comprises a promoter sequence that renders the expression of the ATP1A3-coding nucleic acid sequence CNS-specific.
- the promoters have the ability to drive the ATP1A3 expression in target areas in central nervous system.
- the promoter sequence can be neuron-specific or glia-specific.
- a promoter specific to the gene is incorporated into the AAV construct.
- Inclusion of gene-specific promoters in recombinant AAVs for gene delivery provides the desired specificity for neuronal transduction and expression within particular target cells in the brain that is not possible with promoters with non-specific expression profile, like CMV (Watakabe et al., 2015).
- the use of specific promoters to restrict transgene expression was utilized successfully in several gene delivery studies on non-human primates.
- a 300 bp TH promoter in AAV vector was used to drive expression in dopaminergic neurons of macaques, achieving a specificity of 95% (Stauffer et al., 2016).
- short 530 bp enhancer sequence Dlx was used to drive GFP expression in GABAergic neurons of marmosets, achieving a specificity of 93% (Dimidschstein et al., 2016).
- lkb-long L7/Pcp2 promoter was used to drive ChR2 expression in Purkinje neurons with 96% selectivity (El-Shamayleh et al., 2017).
- the promoter sequence comprises an endogenous ATP1A3 promoter (P ATP1A3 ); a human neuron-specific promoter with a strong bias towards inhibitory neuron (P hSyn ); or an artificial composite promoter comprising CMV enhancer, chicken 3-actin promoter, and MVM intron (P CBh ).
- an endogenous ATP1A3 promoter is employed.
- a pig ATP1A3 promoter is employed.
- a mouse ATP1A3 promoter is employed (see, e.g., SEQ ID NO: 1).
- a primate ATP1A3 promoter is employed.
- a human ATP1A3 promoter is employed.
- the promoter sequence comprises an endogenous ATP1A3 promoter (P ATP1A3 ) consisting of ⁇ 407/+143 of mouse genomic sequence where “/” indicates the transcription start site.
- Mouse ATP1A3 ⁇ 407/+143 promoter sequence is based on minimal pig and rat ATP1A3 promoters that were sufficient for neuronal expression in vivo (Bierie et al., 2005; Henriksen et al., 2013; Pathak et al., 1994). To avoid redundancy in having two ribosome binding sites in the constructs, the promoter is shortened to +143 to exclude endogenous Kozak sequence immediately adjacent to the start codon.
- This minor shortening may not have a significant negative effect on transgene expression, because ⁇ 210/+77 rat sequence of ATP1A3 promoter was sufficient to drive brain-specific transgene expression in mice in vivo (Pathak et al., 1994).
- the promoter sequence comprises 488 bp-long promoter of porcine ATP1A3 closely homologous to human, which was sufficient to drive GFP expression in Zebrafish brain and spinal cord (Henriksen et al., 2013). Because porcine ATP1A3 promoter was sufficient to drive expression in evolutionarily-distant Zebrafish, it may be sufficient to drive expression on closer-related mammal, like the mouse. In total, 550 nt promoter+3 kb cDNA+133nt rabbit beta globin polyA sequence totals 3,683nt and thus fits within the 4.4 kb payload capacity of AAV.
- a 530 bp enhancer sequence Dlx upstream of the promoter may be additionally included (Dimidschstein et al., 2016).
- the cytomegalovirus CMV promoter is employed to drive mouse ATP1A3 cDNA expression.
- the promoter sequence comprises an artificial composite promoter (P CBh ) consisting of CMV enhancer, chicken 3-actin promoter, and MVM intron (Gray et al., 2011).
- This promoter can drive strong, albeit not cell-specific, expression in mammalian cells.
- the promoter sequence comprises a human neuron-specific promoter (P hSyn ) with “strong, but not exclusive bias towards inhibitory neurons” (Nathanson et al., 2009). Because endogenous ATP1A3 is preferentially expressed in GABAergic (inhibitory) neurons, this promoter may be a safe choice to drive ATP1A3 expression in clinically relevant neurons of the AHC mice.
- P hSyn human neuron-specific promoter
- this promoter may be a safe choice to drive ATP1A3 expression in clinically relevant neurons of the AHC mice.
- the nucleic acid regulatory sequence comprises a sequence to regulate ribosome binding and/or translation efficiency of the ATP1A3 gene.
- a Kozak sequence is included to maximize the ribosome binding and translation efficiency of the supplied transgenic ATP1A3.
- GCCACC sequence was included. This sequence represents the most common conserved RBS (ribosome binding site).
- aCCGGAgccacc sequence (SEQ ID NO: 7) was included.
- the sequence to regulate ribosome binding and/or translation efficiency of the ATP1A3 gene is included at the 3′ end of the promoters immediately in front of the ATG start codon of the subsequence ATP1A3 ORF.
- the non-coding region 3′ to the protein-coding sequence may be retained for its transcriptional termination regulatory sequences, such as those which provide for termination and polyadenlylation.
- the transcriptional termination signals may be provided. Where the transcriptional termination signals natively associated with the coding sequence are not satisfactorily functional in the expression host cell, then a different 3′ region, functional in the host cell, may be substituted.
- the nucleic acid regulatory sequence comprises a 3′-UTR sequence that contains a polyadenylation sequence.
- the 3′-UTR sequence is a rabbit beta globin polyadenylation sequence (rBGpA).
- rBGpA rabbit beta globin polyadenylation sequence
- rBGpA 127-bp rabbit beta globin polyadenylation sequence
- the recombinant AAV vector comprises an AAV vector, a P ATP1A3 promoter, and a ATP1A3 cDNA. In certain embodiments, the recombinant AAV vector comprises an AAV9 vector, a P ATP1A3 promoter, a ATP1A3 cDNA, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence.
- the recombinant AAV vector comprises AAV9/P ATP1A3 -ATP1A3 cDNA-rBGpA.
- the recombinant AAV vector comprises SEQ ID NO: 3.
- the recombinant AAV vector comprises an AAV vector, a P hSyn promoter, and a ATP1A3 cDNA. In certain embodiments, the recombinant AAV vector comprises an AAV9 vector, a P hSyn promoter, a ATP1A3 cDNA, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence.
- the recombinant AAV vector comprises AAV9/P hSyn -ATP1A3 cDNA-rBGpA.
- the recombinant AAV vector comprises SEQ ID NO: 4.
- the recombinant AAV vector comprises an AAV vector, a P CBh promoter, and a ATP1A3 cDNA. In certain embodiments, the recombinant AAV vector comprises an AAV9 vector, a P CBh promoter, a ATP1A3 cDNA, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence.
- the recombinant AAV vector comprises AAV9/P CBh -ATP1A3 cDNA-rBGpA.
- the recombinant AAV vector comprises SEQ ID NO: 5.
- Another aspect of the invention relates to a method for treating a subject having a neurological disorder associated with mutations in the ATP1A3 gene.
- the method comprises administering into the central nervous system (CNS) of the subject a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a ATP1A3 protein, thereby restoring some degree of neurological function in said subject.
- CNS central nervous system
- AAV adeno-associated virus
- the neurological disorder may be selected from the group consisting of alternating hemiplegia of childhood (AHC); rapid-onset dystonia-parkinsonism (RDP); cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS); early infantile epileptic encephalopathy (EIEE); relapsing encephalopathy with cerebellar ataxia (RECA); dystonia, dysmorphism, encephalopathy, MRI abnormalities, no hemiplegia (D-DEMO); familial hemiplegic migraine (FHM); childhood onset schizophrenia (COS); childhood rapid onset ataxia (CROA); and auditory neuropathy spectrum disorder (ANSD). All patients with loss-of-function ATP1A3 mutations can benefit directly from the ATP1A3-based gene therapy.
- AHC alternating hemiplegia of childhood
- RDP rapid-onset dystonia-parkinsonism
- CAPOS sensorineural hearing loss
- the method can restore alpha-3-specific NaK-ATPase activity in the central nervous system, thereby restoring some degree of neurological function in symptomatic mammals (animals or humans) with mutations in ATP1A3 gene.
- the method can restore ATP1A3 function in GABAergic neurons in the CNS, which includes Purkinje neurons of the cerebellum.
- Another aspect of the invention relates to a method for delivering to the central nervous system of a mammal, a ATP1A3 DNA that is expressed in a cell of the central nervous system.
- the method comprises administering into the central nervous system of the mammalian a recombinant AAV vector comprising a nucleic acid sequence encoding a ATP1A3 protein, wherein said vector transduces the cell.
- a “subject,” “individual,” or “patient” is used interchangeably herein, which refers to a vertebrate, e.g., a mammal. Mammals include, but are not limited to, mice, rats, simians, humans, farm animals, sport animals, and pets. In certain embodiments, the subject is human.
- the intended developmental stage (age) of the administration into the subject is neonate, pediatric, or juvenile (pre-adult).
- This gene therapy/delivery method has been tested in various available AHC mouse models by injecting ATP1A3 cDNA-carrying AAV capsids into CSF (via intrathecal or intracisternal injection), using a similar method used to rescue adult mouse models of Mucopolysaccharidosis and diabetic neuropathy.
- This approach provides a safer and more imminently testable approach than genomic editing, and a targeted and rapid path to long-term treatment. Because AAV does not integrate into the genome, the methods described herein also mitigate risks associated with unintended off-target effects of genomic editing.
- the recombinant AAV vector may be administered to one or more CNS components selected from the group consisting of cerebrospinal fluid (CSF), cisterna magna (cerebellomedullaris cistern), the spinal cord, brainstem (medulla, pons, and midbrain), hippocampus, cerebellum, diencephalon (thalamus, hypothalamus), and telencephalon (corpus striatum, cerebral cortex, or, within the cortex, the occipital, temporal, parietal or frontal lobes).
- CSF cerebrospinal fluid
- cisterna magna Cerebellomedullaris cistern
- the spinal cord medulla, pons, and midbrain
- brainstem medulla, pons, and midbrain
- hippocampus cerebellum
- diencephalon thalamus, hypothalamus
- telencephalon corpus striatum, cerebral
- the recombinant AAV vector may be delivered to one or more of these CNS components via intracisternal, intrathecal, or intracerebroventricular injection.
- the AAV vector injection can be optimized for cerebellar (Purkinje neuron) targeting.
- Sites of AAV injection can include intravenous, intrathecal (IT), intra-cisterna magna (ICM), intraparenchymal, intraventricular, and intracerebroventricular.
- Intravenous administration of AAV is associated with severe hepatotoxicity risk, immunological response, and is least efficient in CNS penetration due to the blood-brain barrier (Hinderer et al., 2018). Additionally, both intraventricular and intraparenchymal routes require invasive intracranial surgery, and the latter has shown very limited distribution of transduction (Hardcastle et al., 2018).
- CSF cerebrospinal fluid
- Administration of recombinant AAV vector directly into the cerebrospinal fluid (CSF) can deliver the vector directly to the CNS (bypassing the blood brain barrier), distribute it around and throughout the nervous system, and result in wide pattern of neuronal transduction without transfecting internal organs (Federici et al., 2012), thus bypassing immunological response and eliminating the risk of hepatic cytotoxicity associated with intravenous administration (Hinderer et al., 2018).
- CSF delivery of AAV9 is proven safe and highly efficient in targeting the CNS in various mammals, such as adult mice and pigs.
- the intra-cisterna magna (ICM) route of the AAV injection results in superior CNS distribution of AAV vectors compared with other routes of CSF access (Hinderer et al., 2014).
- IT intrathecal
- aAV9 administered directly into the CSF fluid through an intrathecal (IT) route
- IT administration of 2 ⁇ 10 11 vg of AAV9 in pigs resulted in broad spinal motor neuron and extensive cerebellum transduction, with undetectable levels of peripheral organ transduction (Federici et al., 2011).
- Intrathecal delivery of contrast media, anesthetics, chemotherapeutic agents and drugs for dystonia, spasticity or pain is routinely performed in human medicine.
- even less invasive IT injection into lumbar cistern was sufficient to achieve broad and efficient transfection of the spinal cord, pons, cerebellum and other CNS parts in mice (Guo et al., 2016).
- Intrathecal injection is desirable for AAV delivery because it is:
- the injection dosage for the intracerebroventricular, IT, or IV administration into the CSF fluid of a mammal should be an effective dose, or effective multiple doses, of the composition comprising the recombinant AAV vector.
- a single dose may range from 1 ⁇ 10 9 vg (vector genomes)/kg dose to 1 ⁇ 10 15 vg/kg, for instance, from 0.5 ⁇ 10 10 vg dose to 5 ⁇ 10 11 vg/kg, from 1 ⁇ 10 10 vg/kg to 5 ⁇ 10 11 vg/kg, or from 1 ⁇ 10 12 vg/kg to 1 ⁇ 10 14 vg/kg.
- a single dose injected into a mouse brain via intracisternal or intraventricular injection
- the total volume of injected AAV solution is, for example, between 1 to 20 ⁇ l.
- volumes and delivery rates are appropriately scaled.
- volumes of 150 ⁇ l can be safely injected in the primate brain (Janson et al. (2002) Hunt. Gene Ther. 13:1391-1412).
- Treatment may consist of a single injection per target site, or may be repeated in one or more target sites. Injections can be single or multiple, unilateral or bilateral.
- experimental results have proven that the gene-coding AAV9 vectors are capable of transducing cerebellum and increasing a protein and activity levels.
- an endogenous mouse ATP1A3 promoter (P ATP1A3 ) was used in AAV9 vector, and the results show that expression of mCherry protein in the neurons of ventral cerebellum was detected in mice injected with the AAV9 vector with mouse P ATP1A3 promoter driving mCherry.
- SEQ ID NO: 2 The sequence of such recombinant AAV9 is shown in SEQ ID NO: 2.
- results have proven that the gene-coding AAV9 vectors are capable of transducing brainstem and increasing a protein levels.
- the results show the presence of mCherry protein in mouse brainstem following injection of a recombinant vector comprising AAV9/P ATP1A3 -mCherry cDNA-rBGp(A): there were visible quantity of mCherry protein in cross-sections of the six brainstems of injected mice.
- the sequence of such recombinant AAV9 is shown in SEQ ID NO: 2.
- mCherry protein in mouse brainstem following the injection of AAV9/P ATP1A3 -mCherry cDNA-rBGp(A) is significant. This is because for a transgenic protein to be present in detectable amounts in the tissue, a sequential series of processes have to occur:
- exogenous DNA construct from mouse (P ATP1A3 promoter), rabbit (rBGp(A) sequence), jellyfish (mCherry), some generic eukaryotic elements (Kozak sequence), and viral AAV2 DNA (ITR elements).
- mouse P ATP1A3 promoter
- rabbit rBGp(A) sequence
- jellyfish mCherry
- Kozak sequence some generic eukaryotic elements
- viral AAV2 DNA ITR elements
- An exemplary mouse promoter P ATP1A3 sequence (SEQ ID NO: 1) acatactgcaagatggtggcactctggggccctgcattactgcaattcactgggcctttcctccaccctgtatctaccccactcccagaa ggaggcagattccagggtgcctcaccctcaaagcctcggtcccctaagatacctcccctatattgagggggggtctctgagtccccaccctgg ggatgtcccgggatcaccccccccccccccccgcactgtgctcagcttctcagtggcctcagtggcttgcagaaacaaggttggagcggtgagggggg gaagggggagtacagctgcagtactgggggccgggcgcag
- ITR2-Patpla3-mCherry-rBGp(A)-ITR2 GCCACC Kozak sequence Cctgcaggcagctgcgcgctcgctcactgaggccgcccgggcaaagcccgggcgacctttggtcgcccggcctcagt gagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct gcggccgcaCGCGT acatactgcaagatggtggcactctggggccctgcattactgcaattcactgggcctttcccccaccctgtatctaccccactcccagaa ggaggcagattccagggtgcctcaccctcaaagcctccctaagatacctcccctatat
- the promoter sequence is indicated in lower case letters and marked in boldface. This part of the cassette drives transcription of the transgene and defines the cellular specificity of its expression.
- mouse promoter Patp1a3 was used, and may be replaced with the corresponding homologous human sequence for human application, the mouse promoter.
- the ATP1A3 protein-coding sequence is the same in all three sequences, indicated in capital letters, and is represented by the open reading frame (ORF) of the most predominant transcript of mouse ATP1A3 gene.
- this mouse ATP1A3 protein-coding sequence may be replaced with ORF of the corresponding human sequence, which is also the predominant transcript of human ATP1A3 gene.
- This human ORF sequence is below (SEQ ID NO: 6).
- mice models of AHC are available for gene therapy testing in vivo.
- Six distinct mouse strains carrying common AHC-associated ATP1A3 alleles have been generated and characterized. These mouse models phenocopy many clinical symptoms of AHC, demonstrating causality and reproducing the disease severity spectrum observed in AHC patients. These strains thus provide multiple, available, and independent experimental substrates to test the effectiveness of proposed gene delivery in vivo.
- D801N/+ mice were generated via CRISPR-based genomic editing. When introduced into mice, the D801N allele (GAC ⁇ AAC) also contains the PAM-blocking silent L8202L mutation (CTG ⁇ CTA).
- I810N/+ frozen embryos were provided by the strain creator, Dr. Steven Clapcote.
- mouse primary cerebellar (Purkinje cell) culture is transfected with AAV vector carrying 500 pb mouse ATP1A3 promoter and 3 kb cDNA.
- Controls include un-transfected neuron culture, mock transfected neuron culture, and neuron culture transfected with AAV with ATP1A3 promoter-driven GFP.
- Example 1A Determining Whether Delivery of Wild Type ATP1A3 Gene Via CSF is Sufficient to Rescue Mouse ATP1A3 KO Model of AHC
- KO AHC mice models (DeAndrade, or Ikeda a3+/AE2-6 mice, or Lingrel a3+/KOI4 mice) with ATP1A3 carrying AAV vector. Neonates, 2 week old, and 2 month old mice are tested.
- Example 1B Determining Whether Delivery of Wild Type ATP1A3 Gene to CSF is Sufficient to Rescue Mouse ATP1A3 Missense Model of AHC
- Inject available missense AHC mouse models (D801N, D801Y, I810N and E815K) at site determined in (1) above with ATP1A3 carrying AAV vector. Neonates, 2 week old, and 2 month old mice are tested. The test for rescue is as described for KO mice above.
- This example compares specificity and strength of ATP1A3 transgene expression driven by three different AAV9 vectors in mouse brains (AAV vector constructs differ only in their promoter configuration, all the rest of the coding and regulatory DNA sequences are identical among them).
- Vector biodistribution and expression specificity was determined by double labeling with antibodies against mouse ATP1A3 protein with specific neuronal markers such as Calbindin for Purkinje neurons and GAD67 for GABA-ergic neurons.
- the first steps consisted of determining the best antibodies and staining conditions to detect ATP1A3 in mouse brain tissues, and in neuronal subtypes: Purkinje cells in the cerebellum and GABAergic neurons in cortex, hippocampus and basal ganglia.
- mice injected with mCherry and ATP1A3 expressing AAV viruses, as shown in Table 1, below.
- AAV9_PCBh :ATP1A3 Nov. 29, 2018 4-6 M Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 29, 2018 4-7 M Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 30, 2018 4-8 M Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 30, 2018 1.
- Brains received by Novaxia were pre-sliced to isolate the cerebellum, which was dehydrated and included in paraffin blocks. 4 ⁇ m slices were obtained from each cerebellum and put on glass slides.
- ATP1A3 antibodies were tested on hippocampal and cerebellum slices.
- the calbindin antibody was tested on cerebellum slices and the GAD67 antibody was tested on hippocampal slices.
- ATP1A3 a secondary anti-rabbit Alexa 488 antibody was used for detection while for Calbindin and GAD67 and anti-chicken Alexa 594 antibody was used (Invitrogen, 1:400 dilution).
- mCherry detection as mCherry is a red fluorescent protein, an Alexa 594 anti-rat antibody was chosen for mCherry (1:400 dilution).
- mouse cerebella which were injected with AAV viruses
- antigen retrieval was performed at pH8 for all antibodies, and slides were labeled with the anti-mCherry antibody (Molecular Probes #M11217) at 1:200+anti-Calbindin antibody (Synaptic Systems #214006) at 1:200, and anti-ATP1A3 antibody (EMD Millipore antibody #06-172-1) at 1:250+anti-Calbindin antibody (Synaptic Systems #214006) at 1:200.
- Staining involved the following categories of antibodies: ATP1A3 antibodies, Calbindin antibodies, GAD67 antibodies, and mCherry antibodies.
- FIG. 1 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse cerebellum. This ATP1A3 elicitates a good specific signal compared to the signal obtained in the absence of primary antibody, at both antigen retrieval pH. However, a higher signal was obtained with antigen retrieval at pH8. All images were acquired with the same microscope settings (exposure time, image dynamic range).
- FIG. 2 depicts ATP1A3 (Millipore #06-172-1) staining in mouse cerebellum.
- the zoomed image shows the ATP1A3 signal (green fluorescence channel) in the best condition, showing the widespread labeling and higher labeling fluorescence in what appears to be Purkinje cells.
- FIG. 3 depicts ATP1A3 (Millipore #06-172-1) staining in mouse brain at dorsal hippocampus level.
- This ATP1A3 antibody elicitates a good specific signal compared to the signal obtained in the absence of primary antibody, at both antigen retrieval pH. However, a higher signal was obtained with antigen retrieval at pH8. All images were acquired with the same microscope settings (exposure time, image dynamic range).
- FIG. 4 depicts ATP1A3 (Millipore #06-172-1) staining in mouse brain at dorsal hippocampus level.
- the zoomed image shows the ATP1A3 signal (green fluorescence channel) in the best condition, showing the widespread labeling.
- Some cells appear to have higher perinuclear signals in the parietal cortex and in the hippocampus in CA1, CA2-3 and Dentate Gyrus.
- FIG. 5 shows the ATP1A3 (Millipore #06-172-1) staining in the dorsal hippocampus.
- the zoomed image shows the ATP1A3 signal (green fluorescence channel) in the best condition (pH8 antigen retrieval) in the dorsal hippocampus. Arrows show cells with higher labeling.
- FIG. 6 shows the ATP1A3 (Millipore #06-172-1) staining in the parietal cortex.
- the zoomed image shows the ATP1A3 signal (green fluorescence channel) in the best condition (pH8 antigen retrieval), in the parietal cortex. Arrows show examples of cells with higher labeling.
- FIG. 7 depicts Calbindin (Synaptic Systems #214006) staining in mouse cerebellum. This antibody elicited the best specific signal over the negative control in the pH8 antigen retrieval condition.
- FIG. 8 depicts Calbindin (Synaptic Systems #214006) staining in mouse cerebellum.
- the zoomed image shows Purkinje cells labeled by the calbindin antibody using the pH8 antigen retrieval condition.
- FIG. 9 depicts GAD67 (Synaptic Systems #198 006) staining in mouse brain at dorsal hippocampus level.
- FIG. 10 depicts GAD67 (Synaptic Systems #198 006) staining in mouse brain at dorsal hippocampus level, pH8 antigen retrieval protocol.
- the zoomed image over the dorsal hippocampus shows the detection of GABAergic neurons with low fluorescence levels.
- FIG. 11 depicts GAD67 (Millipore #MAB5406) staining in mouse brain at dorsal hippocampus level.
- FIG. 12 depicts GAD67 (Millipore #MAB5406) staining in mouse brain at dorsal hippocampus level, pH8 antigen retrieval protocol.
- the zoomed image over the dorsal hippocampus (pH8 antigen retrieval protocol) shows good detection of GABAergic neurons in the hippocampus and in the cortex.
- FIG. 13 depicts mCherry staining in mouse cerebellum. Intense stainings are seen below the fourth ventricle and around this region. In the cerebellum, the staining is more diffuse, but specific staining is observed compared to negative brains (infected with ATP1A3 AAV viruses).
- FIG. 14 depicts the mouse cerebellum anatomy.
- VERM indicating the Vermal regions, includes: LING Lingula (I); CENT Central lobule; CUL Culmen; DEC Declive (VI); FOTU Folium-tuber vermis (VII); PYR Pyramus (VIII); UVU Uvula (IX); and NOD Nodulus (X).
- HEM indicating the Hemispheric regions, includes: SIM Simple lobule; AN Ansiform lobule; PRM Paramedian lobule; COPY Copula pyramidis; PFL Paraflocculus; and FL Flocculus.
- CBN indicating Cerebellar nuclei, includes: FN Fastigial nucleus; IP Interposed nucleus; DN Dentate nucleus; and VeCB Vestibulocerebellar nucleus.
- FIG. 15 depicts mCherry staining in mouse cerebellum with pH8 antigen retrieval condition.
- the zoomed images are of the red channel. Intense stainings are seen below the fourth ventricle and around this region. In the cerebellum, the staining is more diffuse with occasionally a more intense cell that could be a Purkinje cell.
- FIG. 16 depicts mCherry staining in mouse cerebellum with pH8 antigen retrieval condition.
- the zoomed images are of the red channel at levels of Purkinje cell layers. Arrows show examples of Purkinje cells.
- the Millipore #06-172-1 antibody demonstrated that it was able to detect the target protein, detecting a similar signal as disclosed in the Bottger et al. (2011) publication, in which the specificity of this antibody was shown.
- Calbindin was well detecting by the tested antibody, giving signals that can be segmented for Purkinje cell detection. The best condition was to use antigen retrieval at pH8.
- the GAD67 antibody from Synaptic Systems (#198 006) allowed detecting some GABAergic neurons but with low fluorescence levels over background.
- the GAD67 antibody from Millipore (#MAB5406) allowed detecting GABAergic neurons with good sensitivity and fluorescence levels and can thus be used for further steps of the study plan.
- the mCherry antibody allowed detecting positive cells only in the mCherry infected group, with strong signals below the fourth ventricle but also labelings in other regions. Co-labeling with the Calbindin antibody will allow determining if specific signals are measured in Purkinje cells. The signals in Purkinje cells are not as strong as below the fourth ventricle.
- Calbindin signals allowed determining the localization of Purkinje neurons.
- the ATP1A3 signals were peripheral to cells, so once cells were segmented, ATP1A3 was measured in a ring around the calbindin signal.
- FIG. 17 Cell-by-cell data was fed into the proprietary Cytosurfer software to make cytometric analyses.
- the mean ATP1A3 fluorescence was plotted against cell count ( FIG. 17 ) and the cells from the same groups displayed group by group. The intensity histograms were well superposed.
- a gate was chosen to detect Purkinje cells with higher ATP1A3 intensity ( FIG. 18 ) which should appear if ATP13 intensity is increased.
- FIGS. 19 , 20 , and 21 show the detected Purkinje neurons and the localization of cells with higher mean intensity. These cells are anatomically regularly spread and do not present a gradient from the cisterna magna.
- FIG. 21 most of the cells detected with increased ATP1A3 are false positive due to creases in the cerebellum slice which induces a higher green fluorescence signal.
- mCherry expression was used as a positive control of AAV injection and transgene expression. Cytometric analysis of mCherry intensity in Purkinje neurons showed a similar profile in mCherry infected mice compared to ATP1A3 infected mice ( FIG. 24 ). A few cells with higher mCherry fluorescence were detected, but this was artificial as these higher signals appeared where creases in the tissue were present ( FIG. 25 ). Quantifications support the absence of differences between treatment groups in Purkinje Neurons ( FIG. 26 ) and other cells ( FIG. 27 ).
- mCherry staining was well detected in some brainstems of mCherry-AAV infected brains while no specific signals were present in ATP1A3-AAV infected brains.
- the pattern of mCherry expression was not widespread but instead focalized in discrete regions, which suggests that the injection site was not truly in the Cisterna Magna but rather in the brainstem itself.
- no mCherry expression could be detected ( FIG. 28 ).
- AAV9_PAT ATP1A3 P1A3 infected mCherry brains 127 98.6 123 132 93.9 106 164 118 113 90.2 93.3 86.9 149 123
- ATP1A3 mean fluorescence in subpopulation with higher ATP1A3 AAV9_PAT AAV9_PAT AAV9_ AAV9 P1A3:: P1A3:: Psynapsin:: PCBh:: mCherry ATP1A3 ATP1A3 ATP1A3 0 12 12 6.579797 5.997402 5.9995585 7.1953383 8.75 5.848485 0 6.5679874 6.0148131 8.8166668 7.1851386 6.0072859 7.1872419 10 7.1648367 7.183503 7.1800464 0 0 6.0020599 6.1937063 0 8.5209115 7.1846988 6.5676226 0 0 7.177844 6.0161244
Abstract
This invention relates to a transgenic vector for transducing cells of a mammal's CNS and transgenically expressing a protein in the mammal's CNS. The transgenic vector comprises a virus-derived vector, a nucleic acid sequence encoding the protein, and an endogenous ATP1A3 promoter sequence. This invention also relates to a composition comprising a recombinant AAV vector comprising a nucleic acid sequence encoding a ATP1A3 protein, in a form compatible with administration into the CNS. The invention also relates to a method for treating a subject having a neurological disorder associated with mutations in the ATP1A3 gene and a method for delivering a transgenic ATP1A3 DNA to the central nervous system of a mammal by administering the recombinant AAV vector into the mammal's CNS.
Description
- This application is a continuation application of U.S. patent application Ser. No. 16/379,440, filed Apr. 9, 2019, which claims priority, under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/654,645, filed on Apr. 9, 2018, which is herein incorporated by reference in its entirety.
- The instant application contains a Sequence Listing which has been filed electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Aug. 10, 2023, is named 24892_0200-US-CON_SL.xml and is 25,770 bytes in size.
- The present invention relates to the delivery and expression of ATP1A3 genes in the central nervous system.
- Alternating Hemiplegia of Childhood (AHC) is a serious and rare neurodevelopmental disorder, affecting approximately 1 in 1,000,000 children. AHC is caused by de novo loss-of-function mutations in the ATP1A3 gene (Heinzen et al., 2012; Rosewich et al., 2012). The gene encodes the α3 subunit of the Na+, K+ ATPase, one of two pumps that establish and maintain electrochemical gradients required for the propagation of action potentials in neurons. AHC-associated mutations do not affect expression of ATP1A3 gene or levels of its protein, but significantly reduce α3 protein functionality (Heinzen et al., 2012; Li et al., 2015). Two most common AHC-associated alleles of ATP1A3 cause D801N and E815K missense substitutions (Heinzen et al., 2012; Rosewich et al., 2012; Sasaki et al., 2014; Viollet et al., 2015).
- ATP1A3 gene is expressed in the central nervous system (CNS) and heart of all mammals studied. Brain expression of ATP1A3 is enriched in high frequency GABAergic interneurons of the cerebellum, pons, basal ganglia, thalamus, cortex and hippocampus (Bøttger et al., 2011; Hieber et al., 1991; McGrail et al., 1991; Pietrini et al., 1992; Richards et al., 2007). While most neurons of the CNS also express ATP1A1 gene that can partially compensate for the loss of ATP1A3 functionality, some neuron types, most notably Purkinje cells of the cerebellum and certain inhibitory interneurons with high-frequency firing rate, do not express ATP1A1, leaving them especially vulnerable to ATP1A3 dysfunction. Clinical symptoms of cerebellar, hippocampal, basal ganglia, and motor cortex dysfunction largely correlate with persistent symptoms of AHC. In line with clinical symptoms, brains of AHC patients show progressive frontal dominant cerebral, severe hippocampal, and diffuse cerebellar atrophy (Sasaki et al., 2017). Paroxysmal symptoms of AHC likely originate in Purkinje cells and spread through the afferent networks of the cerebellum by spreading depolarization (“spreading depression”).
- AHC symptoms appear before 18 months of age, and often shortly after birth. AHC causes severe morbidity and increased mortality. Patients often suffer severe neurodevelopmental impairments, episodes of paralysis, severe dystonia, ataxia, swallowing problems, epilepsy, status epilepticus, sudden unexpected death, and episodes of developmental regression (Mikati et al., 2000; Panagiotakaki et al., 2015). Currently, there is no effective on-target treatment, although certain off-target drugs like Flunarizine have been reported to have some limited effect on certain symptoms.
- Besides AHC, mutations in ATP1A3 gene are associated with at least eight other distinct, but clinically overlapping neurological disorders (Dard et al., 2015; de Carvalho Aguiar et al., 2004; Demos et al., 2014; Heinzen et al., 2014; Paciorkowski et al., 2015; Smedemark-Margulies et al., 2016; Sweadner et al., 2016; Sweney et al., 2015; Yano et al., 2017). The clinical symptoms of these diseases partly intersect and range from mild to severe. The number of patients with pathogenic ATP1A3 alleles is likely to increase if ATP1A3 is included in gene panels for epilepsy-like disorders, as these patients are often misdiagnosed (Algahtani et al., 2017).
- There thus remains a need in the art to develop an on-target delivery of ATP1A3 genes and an effective gene therapy treatment of neurological disorders associated with loss-of-function mutations in ATP1A3. This invention answers this need.
- One aspect of the invention relates to a transgenic vector for transducing cells of the central nervous system of a mammal and transgenically expressing a protein in the central nervous system of the mammal. The transgenic vector comprises a virus-derived vector, a nucleic acid sequence encoding the protein, and an endogenous ATP1A3 promoter (PATP1A3) sequence.
- One aspect of the invention relates to a composition comprising a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a ATP1A3 (sodium/potassium-transporting ATPase subunit alpha-3) protein, in a form compatible with administration into the central nervous system.
- Another aspect of the invention relates to a method for treating a subject having a neurological disorder associated with mutations in the ATP1A3 gene. The method comprises administering into the central nervous system (CNS) of the subject a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a ATP1A3 protein, thereby restoring some degree of neurological function in said subject.
- Another aspect of the invention relates to a method for delivering to the central nervous system of a mammal, a ATP1A3 DNA that is expressed in a cell of the central nervous system. The method comprises administering into the central nervous system of the mammalian a recombinant AAV vector comprising a nucleic acid sequence encoding a ATP1A3 protein, wherein said vector transduces the cell.
- Additional aspects, advantages and features of the invention are set forth in this specification, and in part will become apparent to those skilled in the art on examination of the following, or may be learned by practice of the invention. The inventions disclosed in this application are not limited to any particular set of or combination of aspects, advantages and features. It is contemplated that various combinations of the stated aspects, advantages and features make up the inventions disclosed in this application.
-
FIG. 1 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse cerebellum. All images were acquired with the same microscope settings (exposure time, image dynamic range). -
FIG. 2 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse cerebellum, as a zoomed image. -
FIG. 3 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse brain at dorsal hippocampus level. All images were acquired with the same microscope settings (exposure time, image dynamic range). -
FIG. 4 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse brain at dorsal hippocampus level, as a zoomed image. -
FIG. 5 depicts ATP1A3 (Millipore #06-172-1) staining in the dorsal hippocampus, as zoomed image. -
FIG. 6 depicts ATP1A3 (Millipore #06-172-1) staining in the parietal cortex, as a zoomed image. -
FIG. 7 depicts Calbindin (Synaptic Systems #214006) staining in a mouse cerebellum. -
FIG. 8 depicts Calbindin (Synaptic Systems #214006) staining in a mouse cerebellum, as a zoomed image. -
FIG. 9 depicts GAD67 (Synaptic Systems #198 006) staining in a mouse brain at dorsal hippocampus level. -
FIG. 10 depicts GAD67 (Synaptic Systems #198 006) staining in mouse brain at dorsal hippocampus level, pH8 antigen retrieval protocol, as a zoomed image over the dorsal hippocampus. -
FIG. 11 depicts GAD67 (Millipore #MAB5406) staining in a mouse brain at dorsal hippocampus level. -
FIG. 12 depicts: GAD67 (Millipore #MAB5406) staining in mouse brain at dorsal hippocampus level, pH8 antigen retrieval protocol. - Zoomed image over the dorsal hippocampus (pH8 antigen retrieval protocol) showing good detection of GABAergic neurons in the hippocampus and in the cortex.
-
FIG. 13 depicts mCherry staining in a mouse cerebellum. -
FIG. 14 depicts the mouse cerebellum anatomy. -
FIG. 15 depicts mCherry staining in mouse cerebellum with pH8 antigen retrieval condition, as zoomed images. -
FIG. 16 depicts mCherry staining in mouse cerebellum with pH8 antigen retrieval condition, as zoomed images. -
FIG. 17 depicts histograms of the mean intensity of ATP1A3 in the 4 experimental groups. Histograms are well superposed. -
FIG. 18 depicts histograms of the mean intensity of ATP1A3 in the 4 experimental groups with the gate for highest fluorescence levels. -
FIG. 19 depicts an example of Purkinje cell detection. Contours of detected cells are shown. -
FIG. 20 depicts an example of Purkinje cell detection showing cells with higher ATP1A3 levels. Contours of detected cells are shown in dark shading, and cells in gate are shown in light shading. -
FIG. 21 depicts an example of Purkinje cell detection showing cells with higher ATP1A3 levels. Contours of detected cells are shown in dark shading, and cells in gate are shown in light shading. -
FIG. 22 depicts graphical representations of mean ATP1A3 intensity in Purkinje Neurons and percentage of Purkinje neurons with high ATP1A3 intensity. The left graft shows mean intensity in Purkinje Neurons, and the right graph shows the percentage of Purkinje neurons with High ATP1A3 intensity. -
FIG. 23 depicts graphical representations of mean ATP1A3 intensity in cerebellar cells other than Purkinje neurons. -
FIG. 24 depicts a histogram of the mean intensity of mCherry in the mCherry group and animals from ATP1A3 infected groups, with gate for highest fluorescence levels. -
FIG. 25 depicts an example of Purkinje cell detection showing cells with higher mCherry levels (cells in Gate named Highest). Contours of detected cells are shown in black, and cells in gate are shown in dark shading. -
FIG. 26 depicts graphical representations of mean mCherry intensity in Purkinje Neurons and the percentage of Purkinje neurons with high mCherry intensity. The left graft shows the mean intensity in Purkinje Neurons. The right graph shows the percentage of Purkinje neurons with High mCherry intensity. -
FIG. 27 depicts graphical representations of mean mCherry intensity in cerebellar cells other than Purkinje neuron. -
FIG. 28 depicts counts of mCherry positive cells in mCherry infected brainstems. -
FIG. 29 depicts an example of cells with higher ATP1A3. -
FIG. 30 depicts quantification of ATP1A3 immunofluorescence. The left graft shows ATP1A3 immunofluorescence at the surrounding of all detected cells. The middle graft shows the percentage of cells detected as higher expressing ATP1A3 after gating. The right graft shows mean fluorescence in cells in highest ATP1A3 gate. - One aspect of the invention relates to a transgenic vector for transducing cells of the central nervous system of a mammal and transgenically expressing a protein in the central nervous system of the mammal. The transgenic vector comprises a virus-derived vector, a nucleic acid sequence encoding the protein, and an endogenous ATP1A3 promoter (PATP1A3) sequence.
- Suitable viral vectors include those neurotrophic viral vectors, including, but not limited to, adeno-associated viral vectors (AAV), herpes simplex viral vectors and lentiviral vectors. More discussions about the herpes simplex viral vectors may be found in U.S. Pat. No. 5,672,344, which is incorporated herein by reference in its entirety.
- All the descriptions and embodiments relating to the AAV vectors discussed in a different aspect of the invention, infra, are suitable for this aspect of the invention.
- The transgenic vector also comprises a nucleic acid sequence encoding a protein (DNA encoding the protein, e.g., cDNA of protein), the transgene. The transgene encodes a biologically active protein which is transgenically expressed in the central nervous system of a mammal. The transgene may be ATP1A3 (sodium/potassium-transporting ATPase subunit alpha-3). The transgenes may also be insulin growth factor-1 (IGF-1), calbindin D28, parvalbumin, HIF1-alpha, SIRT-2, VEGF, SMN-1, SMN-2, CNTF (Ciliary neurotrophic factor), sonic hedgehog (shh), erythropoietin (EPO), lysyl oxidase (LOX), progranulin, prolactin, ghrelin, neuroserpin, or placenta lactogen.
- The protein-coding nucleic acid may be an DNA sequence, an “exogenous DNA” that is exogenous to both AAV and to the target cell. The DNA may be synthetic DNA, complementary DNA, genomic DNA, or a combination thereof. The DNA may be of any sequence or length, provided that it may be incorporated into the vector and delivered to target cells. Typically, because of the packaging limitations of AAV, the exogenous DNA will have a length of up to 4,400 bases.
- More than one transgene can be delivered by the transgenic vector, e.g., via more than one virus-derived vector. For instance, the transgenic vector comprises multiple AAV vectors and each AAV vector comprises a transgene operably linked to a promoter.
- The protein-coding nucleic acid is operably linked to a promoter sequence to enable the expression of the trangene from a single AAV vector. For the gene to be expressible, the protein-coding nucleic acid shall be operably linked to a promoter sequence so that when the promoter is activated, the coding sequence is transcribed. The protein-coding nucleic acid is operably linked if the linkage does not cause an error in the reading of the downstream sequence. To be “operably linked,” it is not necessary that two sequences be immediately adjacent to one another.
- The promoter sequence drives transcription of the transgene and defines the cellular specificity of its expression. The promoter sequence is an endogenous ATP1A3 promoter (PATP1A3) sequence. In one embodiment, the PATP1A3 promoter comprises a mouse promoter sequence, SEQ ID NO: 1. In one embodiment, the PATP1A3 promoter comprises a homologous human sequence.
- The transgenic vector may further comprise one or more nucleic acid regulatory sequence, linked directly or indirectly to the protein-coding nucleic acid sequence. For instance, a promoter specific to the gene may be incorporated into the transgenic vector. In certain embodiments, the nucleic acid regulatory sequence comprises a sequence to regulate ribosome binding and/or translation efficiency of the ATP1A3 gene. In certain embodiments, the nucleic acid regulatory sequence comprises a 3′-UTR sequence that contains a polyadenylation sequence.
- All the descriptions and embodiments relating to the nucleic acid regulatory sequences discussed in a different aspect of the invention, infra, are suitable for this aspect of the invention.
- In certain embodiments, the transgenic vector comprises an AAV vector (e.g., a recombinant AAV vector), a PATP1A3 promoter, and a mCherry transgene.
- In certain embodiments, the transgenic vector comprises AAV9 vector (e.g., recombinant AAV9 vector), a PATP1A3 promoter, a mCherry transgene, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence. In one embodiment, the transgenic vector comprises SEQ ID NO: 2.
- In certain embodiments, the transgenic vector comprises an AAV vector (e.g., a recombinant AAV vector), a PATP1A3 promoter, and a ATP1A3 transgene.
- In certain embodiments, the transgenic vector comprises AAV9 vector (e.g., recombinant AAV9 vector), a PATP1A3 promoter, a ATP1A3 transgene, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence. In one embodiment, the transgenic vector comprises SEQ ID NO: 3.
- Also disclosed herein are compositions and methods for intracisternal or intrathecal administration of recombinant AAV comprising a gene that affects neurological function. The embodiments of the invention illustrate that some neurological disorders associated with loss-of-function mutations of ATP1A3 genes (e.g., alternating hemiplegia of childhood, “AHC”) can be better addressed with a more targeted delivery of the gene therapy. For instance, the phenotype of an AHC mouse model has been rescued by transgenesis. Inclusion of extra-chromosomal copies of ATP1A3 by transgenesis has been shown to be sufficient to increase Na+, K+ ATPase activity in the brain and confer significant phenotypic improvements compared to non-transgenic mice with the same AHC associated mutation. This demonstrates that the presence of additional copies of functional ATP1A3 genes can compensate for lack of function in a disease-associated genomic allele of ATP1A3 and rescue the associated phenotypes.
- One aspect of the invention relates to a composition comprising a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a ATP1A3 (sodium/potassium-transporting ATPase subunit alpha-3) protein, in a form compatible with administration into the central nervous system.
- The composition contains an adeno-associated virus (AAV) vector. The vector may be a derivative of the adeno-associated virus, into which exogenous DNA is introduced.
- One purpose is to rescue the phenotypes caused by ATP1A3 insufficiency by delivering additional copies of functional ATP1A3 cDNA to the neurons of the CNS. AAV vector is used herein as a carrier to deliver ATP1A3 cDNA.
- AAV is a replication-defective, non-enveloped parvovirus, present in humans and some other primate species but not associated with any pathology. Recombinant AAV vectors are used for the development of human therapeutics because they can infect quiescent non-dividing cells (like neurons), mediate long-term gene expression, and, unlike retroviruses, persist in an extrachromosomal state without integrating into the genome of the host cell. Since AAV does not integrate into the host genome, the use of this viral vector mitigates risks associated with unintended off-target effects of genomic editing (Schaefer et al., 2017; Zhang et al., 2015).
- AAV vectors are derived from single-stranded (ss) DNA parvoviruses that are nonpathogenic for mammals. Briefly, recombinant AAV-based vectors have two open reading frames, the rep and cap viral genes that account for 96% of the viral genome removed, leaving the two flanking 145-basepair (bp) inverted terminal repeats (ITRs), which are used to initiate viral DNA replication, packaging and integration. These ITRs allow for synthesis of the complementary DNA strand. Rep and Cap are translated to produce multiple distinct proteins. When constructing an AAV transfer plasmid, the transgene is placed between the two ITRs, and Rep and Cap are supplied in trans. In the absence of helper virus, wild-type AAV is typically maintained episomally. A single AAV particle can accommodate up to 5 kb of ssDNA, therefore leaving about 4.5 kb for a transgene and regulatory elements, which is typically sufficient. However, trans-splicing systems as described, for example, in U.S. Pat. No. 6,544,785, which is incorporated herein by reference in its entirety, may nearly double this limit.
- In one embodiment, small (4.8 kb) ssDNA AAV genome having ITR sequences flanking the insert are of ITR2 serotype.
- AAV vector of any serotype can be used. Particular useful serotypes are those that are particularly suitable for nervous cells, e.g., AAV1, AAV2, AAV4, AAV5, AAV8, AAV9, AAV-PHP.B, or AAVrh10. Several of these AAV serotypes have been utilized in clinical Phase I and II studies for diseases that require CNS delivery (reviewed in (Naso et al., 2017)). Initial testing of AAV2-based RPE65 delivery has been done in canine culture. Other serotype besides those listed herein can be used. Furthermore, pseudotyped AAV vectors may also be used herein. Pseudotyped AAV vectors are those which contain the genome of one AAV serotype in the capsid of a second AAV serotype; for example, an AAV vector that contains the AAV2 capsid and the AAV1 genome or an AAV vector that contains the AAV5 capsid and the
AAV 2 genome. - Those skilled in the art will be familiar with the preparation of functional AAV-based gene therapy vectors. Methods of AAV production, purification, and preparation for administration to human subjects can also be found in the art (see, e.g., Viral Vectors for Gene Therapy: Methods and Protocols, ed. Machida, Humana Press, 2003, which is incorporated herein by reference in its entirety).
- Additionally, AAV-based gene therapy targeted to cells of the CNS has been described in U.S. Pat. Nos. 6,180,613 and 6,503,888, which are incorporated by reference in their entirety.
- Exemplary AAV vectors are recombinant AAV vectors encoding human protein.
- In certain embodiments, the AAV vector is AAV9 vector. In these embodiments, AAV9 vector is used to deliver a rescue gene to the CNS neurons (e.g., in a mammal, such as mouse, primate, human). Cell-specificity of AAV infection is determined by the capsid serotype. AAV serotype 9 (AAV9) has natural tropism for neurons and was successfully applied to rescue adult mouse models of diseases such as mucopolysaccharidosis (Fu et al., 2010; Hinderer et al., 2016; Watson et al., 2006) and diabetic neuropathy (Homs et al., 2014). Injection of AAV9 into cerebrospinal fluid has been highly efficient in targeting the CNS in adult mice (Bey et al., 2017; Fu et al., 2010) and pigs (Federici et al., 2012). Large comparative analysis of
AAV serotypes - In an illustrative embodiment, the gene therapy is conducted in various mouse models (that phenocopy many clinical symptoms of AHC) by injecting ATP1A3 DNA-carrying AAV9 capsids into cerebrospinal fluid (via injection into cisterna magna), using a similar method used to rescue adult mouse models of Mucopolysaccharidosis (Hinderer et al., 2016; Watson et al., 2006; DiRosario et al., 2010) and diabetic neuropathy (J. Homs et al., 2014).
- The ATP1A3-coding nucleic acid may be a DNA sequence, an “exogenous DNA” that is exogenous to both AAV and to the target cell. For gene therapy of any genetically-based or genetically-acquired neurological disorder in a subject, DNA delivered to that subject may be considered exogenous even though it is identical to a gene native to that subject's species, provided it differs in the regulatory or coding region from the cognate gene of the subject to whom it is delivered, and therefore encodes a different gene product or is expressed to a different degree and/or in different cells, under at least some conditions.
- The DNA may be synthetic DNA, complementary DNA, genomic DNA, or a combination thereof. The DNA may be of any sequence or length, provided that it may be incorporated into the vector and delivered to target cells. Typically, because of the packaging limitations of AAV, the exogenous DNA will have a length of about 10-5,000 bases, e.g., 100 to 4,000 bases. The size of a typical ATP1A3 cDNA (˜3 kb) fits within the carrying capacity of AAV vectors (4.4 kb).
- In one embodiment, a mouse ATP1A3 cDNA sequence is used in ATP1A3-AAV9 vector for gene therapy used in mouse for compatibility. For instance, a sequence of the most common transcript isoform of mouse ATP1A3 gene, NCBI reference sequence NM_001290469.1, may be used. In this embodiment, only the ORF portion of the mRNA is included: from ATG start to TGA stop codons (including the latter).
- In one embodiment, a human ATP1A3 cDNA sequence is used in ATP1A3-AAV9 vector for gene therapy used in human for compatibility. For instance, a sequence of the most abundant transcript of human ATP1A3 gene, NCBI reference sequence NM_152296.4 (SEQ ID NO: 6), may be used.
- In one embodiment, no tags are added to its coding sequence in order not to interfere with transgenic ATP1A3 protein translation, folding, transport and function.
- In the CNS gene therapy applications, it is necessary to control transcriptional activity. Pharmacological regulation of gene expression with the viral vectors can been obtained by including various regulatory elements as described below. The precise nature of regulatory regions needed for gene expression may vary from organism to organism.
- In certain embodiments, the composition further comprises one or more nucleic acid regulatory sequences, linked directly or indirectly to the ATP1A3-coding nucleic acid sequence.
- In certain embodiments, the nucleic acid regulatory sequence comprises a promoter sequence that renders the expression of the ATP1A3-coding nucleic acid sequence CNS-specific. The promoters have the ability to drive the ATP1A3 expression in target areas in central nervous system. The promoter sequence can be neuron-specific or glia-specific.
- In some embodiments, a promoter specific to the gene is incorporated into the AAV construct. Inclusion of gene-specific promoters in recombinant AAVs for gene delivery provides the desired specificity for neuronal transduction and expression within particular target cells in the brain that is not possible with promoters with non-specific expression profile, like CMV (Watakabe et al., 2015). The use of specific promoters to restrict transgene expression was utilized successfully in several gene delivery studies on non-human primates. A 300 bp TH promoter in AAV vector was used to drive expression in dopaminergic neurons of macaques, achieving a specificity of 95% (Stauffer et al., 2016). Similarly, short 530 bp enhancer sequence Dlx was used to drive GFP expression in GABAergic neurons of marmosets, achieving a specificity of 93% (Dimidschstein et al., 2016). lkb-long L7/Pcp2 promoter was used to drive ChR2 expression in Purkinje neurons with 96% selectivity (El-Shamayleh et al., 2017).
- In certain embodiments, the promoter sequence comprises an endogenous ATP1A3 promoter (PATP1A3); a human neuron-specific promoter with a strong bias towards inhibitory neuron (PhSyn); or an artificial composite promoter comprising CMV enhancer, chicken 3-actin promoter, and MVM intron (PCBh).
- In some embodiments, an endogenous ATP1A3 promoter is employed. In one embodiment, a pig ATP1A3 promoter is employed. In one embodiment, a mouse ATP1A3 promoter is employed (see, e.g., SEQ ID NO: 1). In one embodiment, a primate ATP1A3 promoter is employed. In one embodiment, a human ATP1A3 promoter is employed.
- In an illustrative embodiment, the promoter sequence comprises an endogenous ATP1A3 promoter (PATP1A3) consisting of −407/+143 of mouse genomic sequence where “/” indicates the transcription start site. Mouse ATP1A3 −407/+143 promoter sequence is based on minimal pig and rat ATP1A3 promoters that were sufficient for neuronal expression in vivo (Benfante et al., 2005; Henriksen et al., 2013; Pathak et al., 1994). To avoid redundancy in having two ribosome binding sites in the constructs, the promoter is shortened to +143 to exclude endogenous Kozak sequence immediately adjacent to the start codon. This minor shortening may not have a significant negative effect on transgene expression, because −210/+77 rat sequence of ATP1A3 promoter was sufficient to drive brain-specific transgene expression in mice in vivo (Pathak et al., 1994).
- In another illustrative embodiment, the promoter sequence comprises 488 bp-long promoter of porcine ATP1A3 closely homologous to human, which was sufficient to drive GFP expression in Zebrafish brain and spinal cord (Henriksen et al., 2013). Because porcine ATP1A3 promoter was sufficient to drive expression in evolutionarily-distant Zebrafish, it may be sufficient to drive expression on closer-related mammal, like the mouse. In total, 550 nt promoter+3 kb cDNA+133nt rabbit beta globin polyA sequence totals 3,683nt and thus fits within the 4.4 kb payload capacity of AAV.
- Alternatively, in some embodiments, a 530 bp enhancer sequence Dlx upstream of the promoter may be additionally included (Dimidschstein et al., 2016).
- In other embodiments, the cytomegalovirus CMV promoter is employed to drive mouse ATP1A3 cDNA expression.
- In another illustrative embodiment, the promoter sequence comprises an artificial composite promoter (PCBh) consisting of CMV enhancer, chicken 3-actin promoter, and MVM intron (Gray et al., 2011). This promoter can drive strong, albeit not cell-specific, expression in mammalian cells.
- In another illustrative embodiment, the promoter sequence comprises a human neuron-specific promoter (PhSyn) with “strong, but not exclusive bias towards inhibitory neurons” (Nathanson et al., 2009). Because endogenous ATP1A3 is preferentially expressed in GABAergic (inhibitory) neurons, this promoter may be a safe choice to drive ATP1A3 expression in clinically relevant neurons of the AHC mice.
- In certain embodiments, the nucleic acid regulatory sequence comprises a sequence to regulate ribosome binding and/or translation efficiency of the ATP1A3 gene. For instance, a Kozak sequence is included to maximize the ribosome binding and translation efficiency of the supplied transgenic ATP1A3.
- In certain embodiments, GCCACC sequence was included. This sequence represents the most common conserved RBS (ribosome binding site). In certain embodiments, aCCGGAgccacc sequence (SEQ ID NO: 7) was included. In one embodiment, the sequence to regulate ribosome binding and/or translation efficiency of the ATP1A3 gene is included at the 3′ end of the promoters immediately in front of the ATG start codon of the subsequence ATP1A3 ORF.
- The
non-coding region 3′ to the protein-coding sequence may be retained for its transcriptional termination regulatory sequences, such as those which provide for termination and polyadenlylation. By retaining the 3′-region naturally contiguous to the coding sequence, the transcriptional termination signals may be provided. Where the transcriptional termination signals natively associated with the coding sequence are not satisfactorily functional in the expression host cell, then a different 3′ region, functional in the host cell, may be substituted. - In certain embodiments, the nucleic acid regulatory sequence comprises a 3′-UTR sequence that contains a polyadenylation sequence. In one embodiment, the 3′-UTR sequence is a rabbit beta globin polyadenylation sequence (rBGpA). For instance, 127-bp rabbit beta globin polyadenylation (rBGpA) sequence is employed as the 3′UTR due to its small size and proven effectiveness.
- In certain embodiments, the recombinant AAV vector comprises an AAV vector, a PATP1A3 promoter, and a ATP1A3 cDNA. In certain embodiments, the recombinant AAV vector comprises an AAV9 vector, a PATP1A3 promoter, a ATP1A3 cDNA, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence.
- In one embodiment, the recombinant AAV vector comprises AAV9/PATP1A3-ATP1A3 cDNA-rBGpA.
- In one embodiment, the recombinant AAV vector comprises SEQ ID NO: 3.
- In certain embodiments, the recombinant AAV vector comprises an AAV vector, a PhSyn promoter, and a ATP1A3 cDNA. In certain embodiments, the recombinant AAV vector comprises an AAV9 vector, a PhSyn promoter, a ATP1A3 cDNA, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence.
- In one embodiment, the recombinant AAV vector comprises AAV9/PhSyn-ATP1A3 cDNA-rBGpA.
- In one embodiment, the recombinant AAV vector comprises SEQ ID NO: 4.
- In certain embodiments, the recombinant AAV vector comprises an AAV vector, a PCBh promoter, and a ATP1A3 cDNA. In certain embodiments, the recombinant AAV vector comprises an AAV9 vector, a PCBh promoter, a ATP1A3 cDNA, a sequence to regulate ribosome binding and/or translation efficiency, and a 3′-UTR sequence that contains a polyadenylation sequence.
- In one embodiment, the recombinant AAV vector comprises AAV9/PCBh-ATP1A3 cDNA-rBGpA.
- In one embodiment, the recombinant AAV vector comprises SEQ ID NO: 5.
- Another aspect of the invention relates to a method for treating a subject having a neurological disorder associated with mutations in the ATP1A3 gene. The method comprises administering into the central nervous system (CNS) of the subject a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a ATP1A3 protein, thereby restoring some degree of neurological function in said subject.
- Mutations in the ATP1A3 gene alone account for nine different neurological disorders. The neurological disorder may be selected from the group consisting of alternating hemiplegia of childhood (AHC); rapid-onset dystonia-parkinsonism (RDP); cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS); early infantile epileptic encephalopathy (EIEE); relapsing encephalopathy with cerebellar ataxia (RECA); dystonia, dysmorphism, encephalopathy, MRI abnormalities, no hemiplegia (D-DEMO); familial hemiplegic migraine (FHM); childhood onset schizophrenia (COS); childhood rapid onset ataxia (CROA); and auditory neuropathy spectrum disorder (ANSD). All patients with loss-of-function ATP1A3 mutations can benefit directly from the ATP1A3-based gene therapy.
- The method can restore alpha-3-specific NaK-ATPase activity in the central nervous system, thereby restoring some degree of neurological function in symptomatic mammals (animals or humans) with mutations in ATP1A3 gene. The method can restore ATP1A3 function in GABAergic neurons in the CNS, which includes Purkinje neurons of the cerebellum.
- Another aspect of the invention relates to a method for delivering to the central nervous system of a mammal, a ATP1A3 DNA that is expressed in a cell of the central nervous system. The method comprises administering into the central nervous system of the mammalian a recombinant AAV vector comprising a nucleic acid sequence encoding a ATP1A3 protein, wherein said vector transduces the cell.
- A “subject,” “individual,” or “patient” is used interchangeably herein, which refers to a vertebrate, e.g., a mammal. Mammals include, but are not limited to, mice, rats, simians, humans, farm animals, sport animals, and pets. In certain embodiments, the subject is human.
- In certain embodiments, the intended developmental stage (age) of the administration into the subject is neonate, pediatric, or juvenile (pre-adult).
- All the descriptions and embodiments relating to the recombinant AAV vectors, including various AAV vectors, various ATP1A3-coding nucleic acid sequences, and various types of regulator sequences (including promoters, sequences to regulate ribosome binding, and 3′-UTR sequences), discussed in the above aspect of the invention relating to a composition, are applicable for these aspects of the invention relating to a method of treatment or a method of delivery.
- This gene therapy/delivery method has been tested in various available AHC mouse models by injecting ATP1A3 cDNA-carrying AAV capsids into CSF (via intrathecal or intracisternal injection), using a similar method used to rescue adult mouse models of Mucopolysaccharidosis and diabetic neuropathy. This approach provides a safer and more imminently testable approach than genomic editing, and a targeted and rapid path to long-term treatment. Because AAV does not integrate into the genome, the methods described herein also mitigate risks associated with unintended off-target effects of genomic editing.
- In these aspects of the invention relating to a method of treatment or a method of delivery, the recombinant AAV vector may be administered to one or more CNS components selected from the group consisting of cerebrospinal fluid (CSF), cisterna magna (cerebellomedullaris cistern), the spinal cord, brainstem (medulla, pons, and midbrain), hippocampus, cerebellum, diencephalon (thalamus, hypothalamus), and telencephalon (corpus striatum, cerebral cortex, or, within the cortex, the occipital, temporal, parietal or frontal lobes).
- The recombinant AAV vector may be delivered to one or more of these CNS components via intracisternal, intrathecal, or intracerebroventricular injection.
- One purpose is to maximize distribution of the recombinant AAV vector throughout neurons of the CNS. The AAV vector injection can be optimized for cerebellar (Purkinje neuron) targeting.
- Sites of AAV injection can include intravenous, intrathecal (IT), intra-cisterna magna (ICM), intraparenchymal, intraventricular, and intracerebroventricular. Intravenous administration of AAV is associated with severe hepatotoxicity risk, immunological response, and is least efficient in CNS penetration due to the blood-brain barrier (Hinderer et al., 2018). Additionally, both intraventricular and intraparenchymal routes require invasive intracranial surgery, and the latter has shown very limited distribution of transduction (Hardcastle et al., 2018).
- Administration of recombinant AAV vector directly into the cerebrospinal fluid (CSF) can deliver the vector directly to the CNS (bypassing the blood brain barrier), distribute it around and throughout the nervous system, and result in wide pattern of neuronal transduction without transfecting internal organs (Federici et al., 2012), thus bypassing immunological response and eliminating the risk of hepatic cytotoxicity associated with intravenous administration (Hinderer et al., 2018). CSF delivery of AAV9 is proven safe and highly efficient in targeting the CNS in various mammals, such as adult mice and pigs.
- Additionally, direct injection into CSF requires 100×lower dosage than intravenous delivery (Guo et al., 2016). Since transduction rates are highest near the site of delivery, injection of the recombinant vector at the level of cisterna magna (cerebellomedullary cistern, ICM) below the cerebellum can ensure direct and maximal exposure of the vector to cerebellar, hippocampal, brain stem, and cortical regions that show high levels of ATP1A3 expression and are responsible for locomotor and memory impairments in AHC patients.
- The intra-cisterna magna (ICM) route of the AAV injection results in superior CNS distribution of AAV vectors compared with other routes of CSF access (Hinderer et al., 2014).
- Administration of AAV directly into the CSF fluid through an intrathecal (IT) route circulates AAVs throughout the CNS and results in widespread CNS transduction. For example, IT administration of 2×1011 vg of AAV9 in pigs resulted in broad spinal motor neuron and extensive cerebellum transduction, with undetectable levels of peripheral organ transduction (Federici et al., 2011). Intrathecal delivery of contrast media, anesthetics, chemotherapeutic agents and drugs for dystonia, spasticity or pain is routinely performed in human medicine. Alternatively, even less invasive IT injection into lumbar cistern was sufficient to achieve broad and efficient transfection of the spinal cord, pons, cerebellum and other CNS parts in mice (Guo et al., 2016).
- Intrathecal injection is desirable for AAV delivery because it is:
-
- a) less surgically invasive than intracranial delivery method;
- b) more direct and efficient for cerebellar targeting compared to an intravenous method;
- c) less likely to cause peripheral organ toxicity than intravenous method (requires lower 100×lower dosage (Guo et al., 2016));
- d) familiar to medical personnel and widely practiced in human medicine (for other purposes); and
- e) already tested and shown effective for gene delivery into CNS in mice, pigs, and non-human primates.
- The injection dosage for the intracerebroventricular, IT, or IV administration into the CSF fluid of a mammal should be an effective dose, or effective multiple doses, of the composition comprising the recombinant AAV vector. A single dose may range from 1×109 vg (vector genomes)/kg dose to 1×1015 vg/kg, for instance, from 0.5×1010 vg dose to 5×1011 vg/kg, from 1×1010 vg/kg to 5×1011 vg/kg, or from 1×1012 vg/kg to 1×1014 vg/kg. For instance, a single dose injected into a mouse brain (via intracisternal or intraventricular injection) may range from 1×109 vg/kg to 1×1012 vg/kg.
- In experimental mice, the total volume of injected AAV solution is, for example, between 1 to 20 μl. For other mammals, including the human brain, volumes and delivery rates are appropriately scaled. For example, it has been demonstrated that volumes of 150 μl can be safely injected in the primate brain (Janson et al. (2002) Hunt. Gene Ther. 13:1391-1412). Treatment may consist of a single injection per target site, or may be repeated in one or more target sites. Injections can be single or multiple, unilateral or bilateral.
- In an illustrative embodiment, experimental results have proven that the gene-coding AAV9 vectors are capable of transducing cerebellum and increasing a protein and activity levels. For instance, an endogenous mouse ATP1A3 promoter (PATP1A3) was used in AAV9 vector, and the results show that expression of mCherry protein in the neurons of ventral cerebellum was detected in mice injected with the AAV9 vector with mouse PATP1A3 promoter driving mCherry. The sequence of such recombinant AAV9 is shown in SEQ ID NO: 2.
- In another illustrative embodiment, experimental results have proven that the gene-coding AAV9 vectors are capable of transducing brainstem and increasing a protein levels. The results show the presence of mCherry protein in mouse brainstem following injection of a recombinant vector comprising AAV9/PATP1A3-mCherry cDNA-rBGp(A): there were visible quantity of mCherry protein in cross-sections of the six brainstems of injected mice. The sequence of such recombinant AAV9 is shown in SEQ ID NO: 2.
- These results indicate that the endogenous PATP1A3 promoter-containing AAV9 vector can transduce neurons of the CNS in mouse in vivo. The results also indicate that the PATP1A3 promoter supports protein expression in neurons of the brainstem in vivo after 4 weeks. Additionally, the results suggest that the endogenous PATP1A3 promoter-containing AAV9 vector would be able to drive expression (transcription and translation) of the protein code it carries in Purkinje neurons.
- The presence of mCherry protein in mouse brainstem following the injection of AAV9/PATP1A3-mCherry cDNA-rBGp(A) is significant. This is because for a transgenic protein to be present in detectable amounts in the tissue, a sequential series of processes have to occur:
-
- Membrane receptor binding and internalization of the AAV vector from the extracellular space into the intracellular neuronal space.
- Synthesis of the second (complementary) strand on the viral DNA (the injected vector's DNA is single-stranded).
- Transcription: recognition and binding of the expression cassette's regulatory elements by the endogenous transcription machinery, RNA Polymerase and cis-acting transcription factors, in order to synthesize messenger RNA (mRNA) from the DNA.
- Translation: recognition and binding of the regulatory elements in the mRNA by the endogenous translation machinery (ribosome and associated proteins) to synthesize and fold protein based on the mRNA.
The successful completion of each of these processes is critical; if any of these processes is not working, there is no protein expression at the end. Each of these processes requires separate elements to initiate, support, and terminate each process. Therefore, the whole design process is very unpredictable, because there are lots of elements for errors and lots of steps where the process can fail.
- Successful design of a DNA cassette that supports all these processes and that still fits into a AAV9 capsid is therefore significant, because it needs to include not only the coding sequence for the desired protein, but also has all the necessary regulatory elements to support DNA synthesis (second strand) and transcription (mRNA synthesis) and translation processes (protein synthesis and folding).
- In this illustrative example, assembled together was an exogenous DNA construct from mouse (PATP1A3 promoter), rabbit (rBGp(A) sequence), jellyfish (mCherry), some generic eukaryotic elements (Kozak sequence), and viral AAV2 DNA (ITR elements). To generate such an exogenous DNA construct that would be recognized by the endogenous cellular machinery in the mouse CNS to drive the various processes to produce new protein in vivo in an amount that, when distributed throughout the expressing neuron, would be visible in a cross-section of the brainstem—this was a very challenging task, particularly in combination with the another factor that all these elements of the DNA construct need to fit within very stringent size constraints of the DNA load that an AAV vector can carry.
- Therefore, this is a surprising success, even if some DNA elements may have been shown to work elsewhere in other constructs. This is true even though AAV9 serotype is known to have affinity for transfecting neurons (as compared to other AAV types), because the cellular specificity of AAV9 transduction and protein expression is very influenced by the promoter it carries in its DNA (Watakabe et al., 2015). In fact, the specific AAV9 assembly of the parts is new and unique and there is no predictability that all the individual parts would work together (be sufficient to do their job without interfering with the others'). It is the combination of specific capsid serotype and the promoter together that results in the transduction efficiency and cellular tropism (specificity) of transgenic construct expression. The risk factor increases when the DNA construct contains untested components (in this case, the endogenous mouse PATP1A3 promoter).
- The following examples are given as particular embodiments of the invention and to demonstrate the practice and advantages thereof. It is to be understood that the examples are given by way of illustration and are not intended to limit the specification or the claims that follow in any manner.
- Exemplary rAAV9 Sequences:
-
An exemplary mouse promoter PATP1A3 sequence (SEQ ID NO: 1) acatactgcaagatggtggcactctggggccctgcattactgcaattcactgggcctttcctcccaccctgtatctaccccactcccagaa ggaggcagattccagggtgcctcaccctcaaagcctcggtccctaagatacctccctatattgagggggggtctctgagtccccaccctgg ggatgtccgggatcaccccccccccccgcactgtgctcagcttctcagtggccgccactttgcagaaacaaggttggagcggtgagggggg gaagggggagtacagctgcagtactgggggccgggccgcaagctgtccgtctgctcagtactgctcctgattggccggagccgcctcccc ccgcgggcgcgggcatatgaggaggcggaggccccggccgccgcAgcctctgtgcggtgggacccacggaccgacagacgcacgc tcccaccgcggcgcgggcgctgcagaggcccccagcccgagcccgcgcctgagcccatcctgcggccaccgctcatcagtctgaaccc gctcttcccgcgg An exemplary AVV9/PATP1A3-mCherry cDNA-rBGpA sequence (SEQ ID NO: 2). ITR2-Patpla3-mCherry-rBGp(A)-ITR2 GCCACC = Kozak sequence Cctgcaggcagctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagt gagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct gcggccgcaCGCGT acatactgcaagatggtggcactctggggccctgcattactgcaattcactgggcctttcctcccaccctgtatctaccccactcccagaa ggaggcagattccagggtgcctcaccctcaaagcctcggtccctaagatacctccctatattgagggggggtctctgagtccccaccctgg ggatgtccgggatcaccccccccccccgcactgtgctcagcttctcagtggccgccactttgcagaaacaaggttggagcggtgagggggg gaagggggagtacagctgcagtactgggggccgggccgcaagctgtccgtctgctcagtactgctcctgattggccggagccgcctcccc ccgcgggcgcgggcatatgaggaggcggaggccccggccgccgcAgcctctgtgcggtgggacccacggaccgacagacgcacgc tcccaccgcggcgcgggcgctgcagaggcccccagcccgagcccgcgcctgagcccatcctgcggccaccgctcatcagtctgaacg ccgctcttcccgcgg ACCGGTGCCACC atggtgagcaagggcgaggaggataacatggccatcatcaaggagttcatgcgcttcaaggtgcacat ggagggctccgtgaacggccacgagttcgagatcgagggcgagggcgagggccgcccctacgagggcacccagaccgccaagct gaaggtgaccaagggtggccccctgcccttcgcctgggacatcctgtcccctcagttcatgtacggctccaaggcctacgtgaagcacc ccgccgacatccccgactacttgaagctgtccttccccgagggcttcaagtgggagcgcgtgatgaacttcgaggacggcggcgtggt gaccgtgacccaggactcctccctgcaggacggcgagttcatctacaaggtgaagctgcgcggcaccaacttcccctccgacggccc cgtaatgcagaagaagaccatgggctgggaggcctcctccgagcggatgtaccccgaggacggcgccctgaagggcgagatcaag cagaggctgaagctgaaggacggcggccactacgacgctgaggtcaagaccacctacaaggccaagaagcccgtgcagctgccc ggcgcctacaacgtcaacatcaagttggacatcacctcccacaacgaggactacaccatcgtggaacagtacgaacgcgccgaggg ccgccactccaccggcggcatggacgagctgtacaagtaaGTCGACCCGGGCGGCCTCGAGGACGGGGTG AACTACGCCTGAGGATCCGATCTTTTTCCCTCTGCCAAAAATTATGGGGACATCATG AAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATA GTGTGTTGGAATTTTTTGTGTCTCTCACTCGTccggacacgtgcggaccgagcggccgc aggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccg ggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcagg An exemplary PATP1A3-ATP1A3 cDNA-rBGpA sequence (SEQ ID NO: 3). >Mmu-407+143 Atp1a3 Promoter = 550 bp total >mATP1A3 cDNA in capital letters = 3042 bp >rBG poly(A) signal = 131 bp acatactgcaagatggtggcactctggggccctgcattactgcaattcactgggcctttc ctcccaccctgtatctaccccactcccagaaggaggcagattccagggtgcctcaccctc aaagcctcggtccctaagatacctccctatattgagggggggtctctgagtccccaccct ggggatgtccgggatcaccccccccccccgcactgtgctcagcttctcagtggccgccac tttgcagaaacaaggttggagcggtgagggggggaagggggagtacagctgcagtactgg gggccgggccgcaagctgtccgtctgctcagtactgctcctgattggccggagccgcctc cccccgcgggcgcgggcatatgaggaggcggaggccccggccgccgcAgcctctgtgcgg tgggacccacggaccgacagacgcacgctcccaccgcggcgcgggcgctgcagaggcccc cagcccgagcccgcgcctgagcccatcctgcggccaccgctcatcagtctgaacgccgct cttcccgcgg_RE_gccacc ATGGGGGACAAAAAAGATGACAAGAGCTCGCCCAAGAAGAGCAAGGCCAAAGAGC GCCGGGACCTGGATGACCTCAAGAAGGAAGTGGCTATGACAGAGCACAAGATGTCAGTAGAAGAGGTCTGCCGGAAA TACAATACTGACTGCGTGCAGGGTCTGACACACAGTAAAGCCCAGGAGATCCTAGCCCGGGATGGGCCTAACGCCCT CACACCACCGCCCACCACCCCAGAATGGGTCAAGTTCTGCCGGCAGCTGTTTGGTGGCTTCTCTATCCTGCTGTGGA TCGGGGCAATCCTTTGCTTCCTGGCCTATGGCATCCAGGCAGGGACGGAGGATGACCCTTCCGGTGACAATCTGTAC CTGGGCATAGTGCTGGCCGCAGTCGTGATCATCACCGGCTGCTTCTCCTACTACCAAGAAGCCAAGAGTTCTAAGAT CATGGAGTCCTTCAAGAACATGGTCCCCCAGCAAGCCCTTGTGATCCGGGAAGGTGAAAAGATGCAGGTGAATGCGG AGGAGGTGGTGGTCGGGGACCTGGTGGAGATCAAGGGTGGTGACCGGGTGCCAGCTGACCTGCGCATCATCTCGGCC CATGGCTGCAAGGTGGACAACTCCTCCCTGACTGGCGAATCTGAGCCTCAGACCCGCTCCCCGGACTGCACACACGA CAACCCCCTGGAGACTCGGAACATCACCTTCTTTTCCACCAACTGCGTGGAAGGCACCGCTCGGGGTGTGGTGGTAG CCACAGGTGACCGCACCGTCATGGGCCGCATTGCCACCCTGGCCTCGGGCTTGGAGGTGGGCAAGACGCCCATCGCC ATTGAGATTGAGCATTTCATCCAGCTCATTACGGGCGTGGCCGTGTTCCTGGGCGTGTCCTTCTTCATCCTCTCTCT CATTCTGGGTTACACCTGGCTCGAGGCAGTCATCTTCCTCATCGGCATCATTGTGGCCAATGTCCCAGAGGGGCTGC TGGCTACTGTCACGGTGTGTCTGACGCTGACCGCCAAGCGCATGGCTCGCAAGAACTGCCTGGTGAAGAACCTGGAG GCGGTGGAGACGCTGGGCTCCACGTCCACCATCTGCTCGGACAAGACCGGCACTCTCACCCAGAACCGCATGACCGT CGCCCACATGTGGTTTGACAACCAGATCCACGAGGCAGACACCACAGAGGATCAGTCAGGGACCTCTTTCGACAAGA GCTCACACACCTGGGTGGCCCTGTCCCACATCGCCGGGCTCTGCAACCGGGCCGTCTTCAAGGGCGGGCAGGACAAC ATCCCAGTACTCAAGAGGGACGTGGCCGGTGATGCCTCCGAGTCTGCCCTGCTTAAGTGCATTGAGCTGTCCTCGGG TTCCGTAAAGCTGATGCGAGAACGGAACAAGAAAGTGGCTGAGATTCCGTTCAACTCGACCAACAAATACCAGCTAT CCATCCATGAGACTGAGGATCCCAATGACAACCGGTACCTGCTAGTGATGAAGGGCGCCCCCGAACGCATTCTGGAC CGCTGTGCCACCATCCTCCTGCAGGGCAAGGAGCAGCCTCTGGATGAGGAGATGAAGGAGGCCTTCCAGAATGCCTA CCTGGAGCTTGGTGGCCTGGGCGAGCGTGTGCTGGGTTTCTGCCATTACTACCTGCCTGAGGAACAGTTCCCCAAGG GCTTTGCCTTTGACTGTGATGACGTGAACTTCACCACAGACAACCTTTGCTTTGTGGGTCTCATGTCCATGATTGAC CCTCCCCGGGCAGCCGTCCCTGACGCTGTGGGCAAATGCCGAAGCGCAGGCATCAAGGTCATCATGGTCACCGGCGA TCACCCCATCACTGCCAAGGCCATTGCCAAGGGTGTGGGTATCATCTCTGAGGGTAACGAGACTGTCGAAGACATCG CTGCCCGGCTCAACATCCCTGTCAGCCAGGTGAACCCCAGGGATGCCAAAGCCTGTGTGATTCACGGCACCGACCTC AAGGACTTCACCTCGGAGCAGATTGACGAGATTCTGCAGAACCACACCGAGATCGTCTTTGCCCGAACCTCCCCTCA GCAGAAGCTCATCATCGTGGAGGGCTGTCAGAGACAGGGAGCAATTGTGGCTGTGACTGGCGATGGTGTGAATGACT CCCCTGCTCTGAAGAAGGCTGACATCGGGGTGGCCATGGGCATTGCTGGCTCTGATGTCTCTAAGCAGGCTGCCGAC ATGATTCTGCTGGATGACAACTTTGCTTCCATTGTCACTGGTGTGGAGGAAGGCCGCCTGATCTTTGACAACCTGAA GAAATCCATCGCCTACACTCTGACTAGCAACATCCCTGAGATCACACCCTTCCTGCTCTTCATCATGGCTAACATCC CACTGCCTCTTGGCACCATCACCATCCTCTGCATTGACCTGGGTACCGACATGGTCCCTGCAATCTCCCTGGCCTAC GAGGCTGCCGAGAGCGACATCATGAAGAGGCAGCCCAGGAACCCACGCACAGACAAACTGGTCAACGAAAGGCTCAT CAGCATGGCCTACGGGCAGATTGGGATGATCCAGGCCCTCGGTGGTTTCTTCTCCTACTTTGTCATCCTGGCAGAAA ATGGCTTCTTGCCCGGAAACCTGGTGGGCATCCGGCTCAACTGGGATGATCGCACTGTCAATGACCTAGAAGACAGT TATGGGCAGCAGTGGACTTATGAGCAGAGGAAGGTGGTAGAGTTCACATGCCACACAGCCTTCTTTGTGAGTATCGT GGTGGTCCAGTGGGCTGACCTGATCATCTGCAAGACCAGGAGGAACTCCGTCTTCCAGCAGGGCATGAAGAATAAGA TCTTGATCTTCGGCTTGTTTGAGGAGACGGCCCTCGCTGCCTTCCTGTCCTACTGCCCAGGCATGGATGTGGCCCTT CGCATGTACCCTCTCAAGCCCAGCTGGTGGTTCTGTGCCTTCCCCTACAGTTTCCTCATCTTCGTCTATGATGAGAT TCGCAAACTCATCCTGCGCAGGAACCCCGGGGGTTGGGTGGAGAAAGAGACCTACTATTGA_RE_gatctttttc cctctgccaaaaattatggggacatcatgaagccccttgagcatctgacttctggctaataaaggaaatttattttc attgcaatagtgtgttggaattttttgtgtctctcactcggaag An exemplary PCBh-ATP1A3 cDNA-rBGpA sequence (SEQ ID NO: 4). >CBH promoter + Kozak sequence = 811 bp >mATP1A3 cDNA in capital letters = 3042 bp >rBG poly(A) signal = 131 bp cgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaatagtaacgc caatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtat catatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattgtgcccagtacatgacctt atgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtcgaggtgagccccacgttct gcttcactctccccatctcccccccctccccacccccaattttgtatttatttattttttaattattttgtgcagcg atgggggcggggggggggggggggcgcgcgccaggcggggggggcggggcgaggggggggcggggcgaggcggag aggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggcggcggcggcggcggccct ataaaaagcgaagcgcgcggggggggagtcgctgcgacgctgccttcgccccgtgccccgctccgccgccgcctc gcgccgcccgccccggctctgactgaccgcgttactcccacaggtgagcggggggacggcccttctcctccgggct gtaattagctgagcaagaggtaagggtttaagggatggttggttggtggggtattaatgtttaattacctggagcac ctgcctgaaatcactttttttcaggttggaccggt_RE_gccaccATGGGGGACAAAAAAGATGACAAGAGCTCG CCCAAGAAGAGCAAGGCCAAAGAGCGCCGGGACCTGGATGACCTCAAGAAGGAAGTGGCTATGACAGAGCACAAGAT GTCAGTAGAAGAGGTCTGCCGGAAATACAATACTGACTGCGTGCAGGGTCTGACACACAGTAAAGCCCAGGAGATCC TAGCCCGGGATGGGCCTAACGCCCTCACACCACCGCCCACCACCCCAGAATGGGTCAAGTTCTGCCGGCAGCTGTTT GGTGGCTTCTCTATCCTGCTGTGGATCGGGGCAATCCTTTGCTTCCTGGCCTATGGCATCCAGGCAGGGACGGAGGA TGACCCTTCCGGTGACAATCTGTACCTGGGCATAGTGCTGGCCGCAGTCGTGATCATCACCGGCTGCTTCTCCTACT ACCAAGAAGCCAAGAGTTCTAAGATCATGGAGTCCTTCAAGAACATGGTCCCCCAGCAAGCCCTTGTGATCCGGGAA GGTGAAAAGATGCAGGTGAATGCGGAGGAGGTGGTGGTCGGGGACCTGGTGGAGATCAAGGGTGGTGACCGGGTGCC AGCTGACCTGCGCATCATCTCGGCCCATGGCTGCAAGGTGGACAACTCCTCCCTGACTGGCGAATCTGAGCCTCAGA CCCGCTCCCCGGACTGCACACACGACAACCCCCTGGAGACTCGGAACATCACCTTCTTTTCCACCAACTGCGTGGAA GGCACCGCTCGGGGTGTGGTGGTAGCCACAGGTGACCGCACCGTCATGGGCCGCATTGCCACCCTGGCCTCGGGCTT GGAGGTGGGCAAGACGCCCATCGCCATTGAGATTGAGCATTTCATCCAGCTCATTACGGGCGTGGCCGTGTTCCTGG GCGTGTCCTTCTTCATCCTCTCTCTCATTCTGGGTTACACCTGGCTCGAGGCAGTCATCTTCCTCATCGGCATCATT GTGGCCAATGTCCCAGAGGGGCTGCTGGCTACTGTCACGGTGTGTCTGACGCTGACCGCCAAGCGCATGGCTCGCAA GAACTGCCTGGTGAAGAACCTGGAGGCGGTGGAGACGCTGGGCTCCACGTCCACCATCTGCTCGGACAAGACCGGCA CTCTCACCCAGAACCGCATGACCGTCGCCCACATGTGGTTTGACAACCAGATCCACGAGGCAGACACCACAGAGGAT CAGTCAGGGACCTCTTTCGACAAGAGCTCACACACCTGGGTGGCCCTGTCCCACATCGCCGGGCTCTGCAACCGGGC CGTCTTCAAGGGCGGGCAGGACAACATCCCAGTACTCAAGAGGGACGTGGCCGGTGATGCCTCCGAGTCTGCCCTGC TTAAGTGCATTGAGCTGTCCTCGGGTTCCGTAAAGCTGATGCGAGAACGGAACAAGAAAGTGGCTGAGATTCCGTTC AACTCGACCAACAAATACCAGCTATCCATCCATGAGACTGAGGATCCCAATGACAACCGGTACCTGCTAGTGATGAA GGGCGCCCCCGAACGCATTCTGGACCGCTGTGCCACCATCCTCCTGCAGGGCAAGGAGCAGCCTCTGGATGAGGAGA TGAAGGAGGCCTTCCAGAATGCCTACCTGGAGCTTGGTGGCCTGGGCGAGCGTGTGCTGGGTTTCTGCCATTACTAC CTGCCTGAGGAACAGTTCCCCAAGGGCTTTGCCTTTGACTGTGATGACGTGAACTTCACCACAGACAACCTTTGCTT TGTGGGTCTCATGTCCATGATTGACCCTCCCCGGGCAGCCGTCCCTGACGCTGTGGGCAAATGCCGAAGCGCAGGCA TCAAGGTCATCATGGTCACCGGCGATCACCCCATCACTGCCAAGGCCATTGCCAAGGGTGTGGGTATCATCTCTGAG GGTAACGAGACTGTCGAAGACATCGCTGCCCGGCTCAACATCCCTGTCAGCCAGGTGAACCCCAGGGATGCCAAAGC CTGTGTGATTCACGGCACCGACCTCAAGGACTTCACCTCGGAGCAGATTGACGAGATTCTGCAGAACCACACCGAGA TCGTCTTTGCCCGAACCTCCCCTCAGCAGAAGCTCATCATCGTGGAGGGCTGTCAGAGACAGGGAGCAATTGTGGCT GTGACTGGCGATGGTGTGAATGACTCCCCTGCTCTGAAGAAGGCTGACATCGGGGTGGCCATGGGCATTGCTGGCTC TGATGTCTCTAAGCAGGCTGCCGACATGATTCTGCTGGATGACAACTTTGCTTCCATTGTCACTGGTGTGGAGGAAG GCCGCCTGATCTTTGACAACCTGAAGAAATCCATCGCCTACACTCTGACTAGCAACATCCCTGAGATCACACCCTTC CTGCTCTTCATCATGGCTAACATCCCACTGCCTCTTGGCACCATCACCATCCTCTGCATTGACCTGGGTACCGACAT GGTCCCTGCAATCTCCCTGGCCTACGAGGCTGCCGAGAGCGACATCATGAAGAGGCAGCCCAGGAACCCACGCACAG ACAAACTGGTCAACGAAAGGCTCATCAGCATGGCCTACGGGCAGATTGGGATGATCCAGGCCCTCGGTGGTTTCTTC TCCTACTTTGTCATCCTGGCAGAAAATGGCTTCTTGCCCGGAAACCTGGTGGGCATCCGGCTCAACTGGGATGATCG CACTGTCAATGACCTAGAAGACAGTTATGGGCAGCAGTGGACTTATGAGCAGAGGAAGGTGGTAGAGTTCACATGCC ACACAGCCTTCTTTGTGAGTATCGTGGTGGTCCAGTGGGCTGACCTGATCATCTGCAAGACCAGGAGGAACTCCGTC TTCCAGCAGGGCATGAAGAATAAGATCTTGATCTTCGGCTTGTTTGAGGAGACGGCCCTCGCTGCCTTCCTGTCCTA CTGCCCAGGCATGGATGTGGCCCTTCGCATGTACCCTCTCAAGCCCAGCTGGTGGTTCTGTGCCTTCCCCTACAGTT TCCTCATCTTCGTCTATGATGAGATTCGCAAACTCATCCTGCGCAGGAACCCCGGGGGTTGGGTGGAGAAAGAGACC TACTATTGA_RE_gatctttttccctctgccaaaaattatggggacatcatgaagccccttgagcatctgacttc tggctaataaaggaaatttattttcattgcaatagtgtgttggaattttttgtgtctctcactcggaag An exemplary PhSyn-ATP1A3 cDNA-rBGpA sequence (SEQ ID NO: 5). >hSyn Promoter = 500 bp total (includes Kozak sequence) >mATP1A3 cDNA in capital letters = 3042 bp >rBG poly(A) signal = 131 bp ttaattaaactagacagactgcagagggccctgcgtatgagtgcaagtgggttttaggaccaggatgaggcggggtg ggggtgcctacctgacgaccgaccccgacccactggacaagcacccaacccccattccccaaattgcgcatccccta tcagagagggggaggggaaacaggatgcggcgaggcgcgtcgcgactgccagcttcagcaccgcggacagtgccttc gcccccgcctggcggcgcgcgccaccgccgcctcagcactgaaggcgcgctgacgtcactcgccggtcccccgcaaa ctccccttcccggccaccttggtcgcgtccgcgccgccgccggcccagccggaccgcaccacgcgaggcgcgagata ggggggcacgggcgcgaccatctgcgctgcggcgccggcgactcagcgctgcctcagtctgcggtgggcagcggagg agtcgtgtcgtgcctgagagcgcagtcgagag_RE_gccaccATGGGGGACAAAAAAGATGACAAGAGCTCGCCC AAGAAGAGCAAGGCCAAAGAGCGCCGGGACCTGGATGACCTCAAGAAGGAAGTGGCTATGACAGAGCACAAGATGTC AGTAGAAGAGGTCTGCCGGAAATACAATACTGACTGCGTGCAGGGTCTGACACACAGTAAAGCCCAGGAGATCCTAG CCCGGGATGGGCCTAACGCCCTCACACCACCGCCCACCACCCCAGAATGGGTCAAGTTCTGCCGGCAGCTGTTTGGT GGCTTCTCTATCCTGCTGTGGATCGGGGCAATCCTTTGCTTCCTGGCCTATGGCATCCAGGCAGGGACGGAGGATGA CCCTTCCGGTGACAATCTGTACCTGGGCATAGTGCTGGCCGCAGTCGTGATCATCACCGGCTGCTTCTCCTACTACC AAGAAGCCAAGAGTTCTAAGATCATGGAGTCCTTCAAGAACATGGTCCCCCAGCAAGCCCTTGTGATCCGGGAAGGT GAAAAGATGCAGGTGAATGCGGAGGAGGTGGTGGTCGGGGACCTGGTGGAGATCAAGGGTGGTGACCGGGTGCCAGC TGACCTGCGCATCATCTCGGCCCATGGCTGCAAGGTGGACAACTCCTCCCTGACTGGCGAATCTGAGCCTCAGACCC GCTCCCCGGACTGCACACACGACAACCCCCTGGAGACTCGGAACATCACCTTCTTTTCCACCAACTGCGTGGAAGGC ACCGCTCGGGGTGTGGTGGTAGCCACAGGTGACCGCACCGTCATGGGCCGCATTGCCACCCTGGCCTCGGGCTTGGA GGTGGGCAAGACGCCCATCGCCATTGAGATTGAGCATTTCATCCAGCTCATTACGGGCGTGGCCGTGTTCCTGGGCG TGTCCTTCTTCATCCTCTCTCTCATTCTGGGTTACACCTGGCTCGAGGCAGTCATCTTCCTCATCGGCATCATTGTG GCCAATGTCCCAGAGGGGCTGCTGGCTACTGTCACGGTGTGTCTGACGCTGACCGCCAAGCGCATGGCTCGCAAGAA CTGCCTGGTGAAGAACCTGGAGGCGGTGGAGACGCTGGGCTCCACGTCCACCATCTGCTCGGACAAGACCGGCACTC TCACCCAGAACCGCATGACCGTCGCCCACATGTGGTTTGACAACCAGATCCACGAGGCAGACACCACAGAGGATCAG TCAGGGACCTCTTTCGACAAGAGCTCACACACCTGGGTGGCCCTGTCCCACATCGCCGGGCTCTGCAACCGGGCCGT CTTCAAGGGCGGGCAGGACAACATCCCAGTACTCAAGAGGGACGTGGCCGGTGATGCCTCCGAGTCTGCCCTGCTTA AGTGCATTGAGCTGTCCTCGGGTTCCGTAAAGCTGATGCGAGAACGGAACAAGAAAGTGGCTGAGATTCCGTTCAAC TCGACCAACAAATACCAGCTATCCATCCATGAGACTGAGGATCCCAATGACAACCGGTACCTGCTAGTGATGAAGGG CGCCCCCGAACGCATTCTGGACCGCTGTGCCACCATCCTCCTGCAGGGCAAGGAGCAGCCTCTGGATGAGGAGATGA AGGAGGCCTTCCAGAATGCCTACCTGGAGCTTGGTGGCCTGGGCGAGCGTGTGCTGGGTTTCTGCCATTACTACCTG CCTGAGGAACAGTTCCCCAAGGGCTTTGCCTTTGACTGTGATGACGTGAACTTCACCACAGACAACCTTTGCTTTGT GGGTCTCATGTCCATGATTGACCCTCCCCGGGCAGCCGTCCCTGACGCTGTGGGCAAATGCCGAAGCGCAGGCATCA AGGTCATCATGGTCACCGGCGATCACCCCATCACTGCCAAGGCCATTGCCAAGGGTGTGGGTATCATCTCTGAGGGT AACGAGACTGTCGAAGACATCGCTGCCCGGCTCAACATCCCTGTCAGCCAGGTGAACCCCAGGGATGCCAAAGCCTG TGTGATTCACGGCACCGACCTCAAGGACTTCACCTCGGAGCAGATTGACGAGATTCTGCAGAACCACACCGAGATCG TCTTTGCCCGAACCTCCCCTCAGCAGAAGCTCATCATCGTGGAGGGCTGTCAGAGACAGGGAGCAATTGTGGCTGTG ACTGGCGATGGTGTGAATGACTCCCCTGCTCTGAAGAAGGCTGACATCGGGGTGGCCATGGGCATTGCTGGCTCTGA TGTCTCTAAGCAGGCTGCCGACATGATTCTGCTGGATGACAACTTTGCTTCCATTGTCACTGGTGTGGAGGAAGGCC GCCTGATCTTTGACAACCTGAAGAAATCCATCGCCTACACTCTGACTAGCAACATCCCTGAGATCACACCCTTCCTG CTCTTCATCATGGCTAACATCCCACTGCCTCTTGGCACCATCACCATCCTCTGCATTGACCTGGGTACCGACATGGT CCCTGCAATCTCCCTGGCCTACGAGGCTGCCGAGAGCGACATCATGAAGAGGCAGCCCAGGAACCCACGCACAGACA AACTGGTCAACGAAAGGCTCATCAGCATGGCCTACGGGCAGATTGGGATGATCCAGGCCCTCGGTGGTTTCTTCTCC TACTTTGTCATCCTGGCAGAAAATGGCTTCTTGCCCGGAAACCTGGTGGGCATCCGGCTCAACTGGGATGATCGCAC TGTCAATGACCTAGAAGACAGTTATGGGCAGCAGTGGACTTATGAGCAGAGGAAGGTGGTAGAGTTCACATGCCACA CAGCCTTCTTTGTGAGTATCGTGGTGGTCCAGTGGGCTGACCTGATCATCTGCAAGACCAGGAGGAACTCCGTCTTC CAGCAGGGCATGAAGAATAAGATCTTGATCTTCGGCTTGTTTGAGGAGACGGCCCTCGCTGCCTTCCTGTCCTACTG CCCAGGCATGGATGTGGCCCTTCGCATGTACCCTCTCAAGCCCAGCTGGTGGTTCTGTGCCTTCCCCTACAGTTTCC TCATCTTCGTCTATGATGAGATTCGCAAACTCATCCTGCGCAGGAACCCCGGGGGTTGGGTGGAGAAAGAGACCTAC TATTGA_RE_gatctttttccctctgccaaaaattatggggacatcatgaagccccttgagcatctgacttctgg ctaataaaggaaatttattttcattgcaatagtgtgttggaattttttgtgtctctcactcggaag - In the above three sequences, the promoter sequence is indicated in lower case letters and marked in boldface. This part of the cassette drives transcription of the transgene and defines the cellular specificity of its expression. In the first sequence, mouse promoter Patp1a3 was used, and may be replaced with the corresponding homologous human sequence for human application, the mouse promoter.
- Ribosome binding site (=upstream regulatory bit) is indicated in lower case letters and marked in red, and is separated from the promoter sequence by “_RE_”.
- 3′UTR and poly(A) signal (=downstream regulatory bit) is indicated in lower case letters and marked in green, and is separated from the ATP1A3 protein-coding sequence by “_RE_”.
- The ATP1A3 protein-coding sequence is the same in all three sequences, indicated in capital letters, and is represented by the open reading frame (ORF) of the most predominant transcript of mouse ATP1A3 gene.
- For human application, this mouse ATP1A3 protein-coding sequence may be replaced with ORF of the corresponding human sequence, which is also the predominant transcript of human ATP1A3 gene. This human ORF sequence is below (SEQ ID NO: 6).
-
>Hsa_ATP1A3_isoform_1_NM_152296.4 ATGGGGGACAAGAAAGATGACAAGGACTCACCCAAGAAGAACAAGGGCAAGGAGCGCCGGGACCTGGATG ACCTCAAGAAGGAGGTGGCTATGACAGAGCACAAGATGTCAGTGGAAGAGGTCTGCCGGAAATACAACAC AGACTGTGTGCAGGGTTTGACCCACAGCAAAGCCCAGGAGATCCTGGCCCGGGATGGGCCTAACGCACTC ACGCCACCGCCTACCACCCCAGAGTGGGTCAAGTTTTGCCGGCAGCTCTTCGGGGGCTTCTCCATCCTGC TGTGGATCGGGGCTATCCTCTGCTTCCTGGCCTACGGTATCCAGGCGGGCACCGAGGACGACCCCTCTGG TGACAACCTGTACCTGGGCATCGTGCTGGCGGCCGTGGTGATCATCACTGGCTGCTTCTCCTACTACCAG GAGGCCAAGAGCTCCAAGATCATGGAGTCCTTCAAGAACATGGTGCCCCAGCAAGCCCTGGTGATCCGGG AAGGTGAGAAGATGCAGGTGAACGCTGAGGAGGTGGTGGTCGGGGACCTGGTGGAGATCAAGGGTGGAGA CCGAGTGCCAGCTGACCTGCGGATCATCTCAGCCCACGGCTGCAAGGTGGACAACTCCTCCCTGACTGGC GAATCCGAGCCCCAGACTCGCTCTCCCGACTGCACTCACGACAACCCCTTGGAGACTCGGAACATCACCT TCTTTTCCACCAACTGTGTGGAAGGCACGGCTCGGGGCGTGGTGGTGGCCACGGGCGACCGCACTGTCAT GGGCCGTATCGCCACCCTGGCATCAGGGCTGGAGGTGGGCAAGACGCCCATCGCCATCGAGATTGAGCAC TTCATCCAGCTCATCACCGGCGTGGCTGTCTTCCTGGGTGTCTCCTTCTTCATCCTCTCCCTCATTCTCG GATACACCTGGCTTGAGGCTGTCATCTTCCTCATCGGCATCATCGTGGCCAATGTCCCAGAGGGTCTGCT GGCCACTGTCACTGTGTGTCTGACGCTGACCGCCAAGCGCATGGCCCGGAAGAACTGCCTGGTGAAGAAC CTGGAGGCTGTAGAAACCCTGGGCTCCACGTCCACCATCTGCTCAGATAAGACAGGGACCCTCACTCAGA ACCGCATGACAGTCGCCCACATGTGGTTTGACAACCAGATCCACGAGGCTGACACCACTGAGGACCAGTC AGGGACCTCATTTGACAAGAGTTCGCACACCTGGGTGGCCCTGTCTCACATCGCTGGGCTCTGCAATCGC GCTGTCTTCAAGGGTGGTCAGGACAACATCCCTGTGCTCAAGAGGGATGTGGCTGGGGATGCGTCTGAGT CTGCCCTGCTCAAGTGCATCGAGCTGTCCTCTGGCTCCGTGAAGCTGATGCGTGAACGCAACAAGAAAGT GGCTGAGATTCCCTTCAATTCCACCAACAAATACCAGCTCTCCATCCATGAGACCGAGGACCCCAACGAC AACCGATACCTGCTGGTGATGAAGGGTGCCCCCGAGCGCATCCTGGACCGCTGCTCCACCATCCTGCTAC AGGGCAAGGAGCAGCCTCTGGACGAGGAAATGAAGGAGGCCTTCCAGAATGCCTACCTTGAGCTCGGTGG CCTGGGCGAGCGCGTGCTTGGTTTCTGCCATTATTACCTGCCCGAGGAGCAGTTCCCCAAGGGCTTTGCC TTCGACTGTGATGACGTGAACTTCACCACGGACAACCTCTGCTTTGTGGGCCTCATGTCCATGATCGACC CACCCCGGGCAGCCGTCCCTGACGCGGTGGGCAAGTGTCGCAGCGCAGGCATCAAGGTCATCATGGTCAC CGGCGATCACCCCATCACGGCCAAGGCCATTGCCAAGGGTGTGGGCATCATCTCTGAGGGCAACGAGACT GTGGAGGACATCGCCGCCCGGCTCAACATTCCCGTCAGCCAGGTTAACCCCCGGGATGCCAAGGCCTGCG TGATCCACGGCACCGACCTCAAGGACTTCACCTCCGAGCAAATCGACGAGATCCTGCAGAATCACACCGA GATCGTCTTCGCCCGCACATCCCCCCAGCAGAAGCTCATCATTGTGGAGGGCTGTCAGAGACAGGGTGCA ATTGTGGCTGTGACCGGGGATGGTGTGAACGACTCCCCCGCTCTGAAGAAGGCCGACATTGGGGTGGCCA TGGGCATCGCTGGCTCTGACGTCTCCAAGCAGGCAGCTGACATGATCCTGCTGGACGACAACTTTGCCTC CATCGTCACAGGGGTGGAGGAGGGCCGCCTGATCTTCGACAACCTAAAGAAGTCCATTGCCTACACCCTG ACCAGCAATATCCCGGAGATCACGCCCTTCCTGCTGTTCATCATGGCCAACATCCCGCTGCCCCTGGGCA CCATCACCATCCTCTGCATCGATCTGGGCACTGACATGGTCCCTGCCATCTCACTGGCGTACGAGGCTGC CGAAAGCGACATCATGAAGAGACAGCCCAGGAACCCGCGGACGGACAAATTGGTCAATGAGAGACTCATC AGCATGGCCTACGGGCAGATTGGAATGATCCAGGCTCTCGGTGGCTTCTTCTCTTACTTTGTGATCCTGG CAGAAAATGGCTTCTTGCCCGGCAACCTGGTGGGCATCCGGCTGAACTGGGATGACCGCACCGTCAATGA CCTGGAAGACAGTTACGGGCAGCAGTGGACATACGAGCAGAGGAAGGTGGTGGAGTTCACCTGCCACACG GCCTTCTTTGTGAGCATCGTTGTCGTCCAGTGGGCCGATCTGATCATCTGCAAGACCCGGAGGAACTCGG TCTTCCAGCAGGGCATGAAGAACAAGATCCTGATCTTCGGGCTGTTTGAGGAGACGGCCCTGGCTGCCTT CCTGTCCTACTGCCCCGGCATGGACGTGGCCCTGCGCATGTACCCTCTCAAGCCCAGCTGGTGGTTCTGT GCCTTCCCCTACAGTTTCCTCATCTTCGTCTACGACGAAATCCGCAAACTCATCCTGCGCAGGAACCCAG GGGGTTGGGTGGAGAAGGAAACCTACTACTGA - Several mouse models of AHC are available for gene therapy testing in vivo. Six distinct mouse strains carrying common AHC-associated ATP1A3 alleles have been generated and characterized. These mouse models phenocopy many clinical symptoms of AHC, demonstrating causality and reproducing the disease severity spectrum observed in AHC patients. These strains thus provide multiple, available, and independent experimental substrates to test the effectiveness of proposed gene delivery in vivo.
-
TABLE 1 Comparison of clinical features in alternating hemiplegia of childhood and ATP1A3 mouse models Clinical Mouse models with ATP1A3 missense mutations disorder Mashlool Myshkin Matoub AHC D801N/+ I810N/+ E815K/+ D801Y/+ Symptoms Hemiplegic episodes + + * + − Dystonia + + * + + Abnormal motor + + + + + control/ataxia Spontaneous seizures + + + + − SUDEP + + + + Learning and memory + + + + + impairments Impulsivity/Increased + + + − + activity in open field Abnormal eye + − − − − movements +, feature usually occurs; −, feature not described * Limb clasping, hindlimb splaying and hindlimb dragging - D801N/+ mice were generated via CRISPR-based genomic editing. When introduced into mice, the D801N allele (GAC→AAC) also contains the PAM-blocking silent L8202L mutation (CTG→CTA).
- I810N/+ frozen embryos were provided by the strain creator, Dr. Steven Clapcote.
- To determine vector feasibility, mouse primary cerebellar (Purkinje cell) culture is transfected with AAV vector carrying 500 pb mouse ATP1A3 promoter and 3 kb cDNA.
- Controls include un-transfected neuron culture, mock transfected neuron culture, and neuron culture transfected with AAV with ATP1A3 promoter-driven GFP.
- Levels of ATP1A3 expression are quantified in each using RT-PCR and Western of lysates.
- Inject available KO AHC mice models (DeAndrade, or Ikeda a3+/AE2-6 mice, or Lingrel a3+/KOI4 mice) with ATP1A3 carrying AAV vector. Neonates, 2 week old, and 2 month old mice are tested.
-
- Negative control comprises injection of AHC mice with empty AAV vector.
- Positive control comprises injection of wild type mice at same age, with same vector.
- Test to measure rescue (Rely on specific known expertise in characterizing the mouse)
- Follow-up tests: Harvest brains, check ATP1a3 protein and mRNA levels using immunohistochemistry and/or antisense oligo in target brain areas: cerebellum, DCN, brain stem, PV+ interneurons, hippocampus, basal ganglia, thalamus, corpus callosum, and motor cortex.
- Inject available missense AHC mouse models (D801N, D801Y, I810N and E815K) at site determined in (1) above with ATP1A3 carrying AAV vector. Neonates, 2 week old, and 2 month old mice are tested. The test for rescue is as described for KO mice above.
- This example compares specificity and strength of ATP1A3 transgene expression driven by three different AAV9 vectors in mouse brains (AAV vector constructs differ only in their promoter configuration, all the rest of the coding and regulatory DNA sequences are identical among them).
- Vector biodistribution and expression specificity was determined by double labeling with antibodies against mouse ATP1A3 protein with specific neuronal markers such as Calbindin for Purkinje neurons and GAD67 for GABA-ergic neurons.
- The first steps consisted of determining the best antibodies and staining conditions to detect ATP1A3 in mouse brain tissues, and in neuronal subtypes: Purkinje cells in the cerebellum and GABAergic neurons in cortex, hippocampus and basal ganglia.
- Wild type mouse brain embedded in paraffin, sliced at the level of dorsal hippocampus and in the cerebellum.
- Mice injected with mCherry and ATP1A3 expressing AAV viruses, as shown in Table 1, below.
-
TABLE 1 Animal Date # Sex DOB Treatment Group Injection 1-1 F Oct. 30, 2018 AAV9_PATP1A3::mCherry Nov. 26, 2018 1-2 F Oct. 30, 2018 AAV9_PATP1A3::mCherry Nov. 26, 2018 1-3 LL Oct. 30, 2018 AAV9_PATP1A3::mCherry Nov. 27, 2018 1-4 F Oct. 30, 2018 AAV9_PATP1A3::mCherry Nov. 27, 2018 1-5 M Oct. 30, 2018 AAV9_PATP1A3::mCherry Nov. 29, 2018 1-6 M Oct. 30, 2018 AAV9_PATP1A3::mCherry Nov. 29, 2018 1-7 M Oct. 30, 2018 AAV9_PATP1A3::mCherry Nov. 30, 2018 1-8 M Oct. 30, 2018 AAV9_PATP1A3::mCherry Nov. 30, 2018 2-1 F Oct. 30, 2018 AAV9_PATP1A3::ATP1A3 Nov. 26, 2018 2-2 F Oct. 30, 2018 AAV9_PATP1A3::ATP1A3 Nov. 26, 2018 2-3 F Oct. 30, 2018 AAV9_PATP1A3::ATP1A3 Nov. 27, 2018 2-4 F Oct. 30, 2018 AAV9_PATP1A3::ATP1A3 Nov. 27, 2018 2-5 M Oct. 30, 2018 AAV9_PATP1A3::ATP1A3 Nov. 29, 2018 2-6 M Oct. 30, 2018 AAV9_PATP1A3::ATP1A3 Nov. 29, 2018 2-7 M Oct. 30, 2018 AAV9_PATP1A3::ATP1A3 Nov. 30, 2018 2-8 M Oct. 30, 2018 AAV9_PATP1A3::ATP1A3 Nov. 30, 2018 3-1 F Oct. 30, 2018 AAV9_PSyn::ATP1A3 Nov. 26, 2018 3-2 F Oct. 30, 2018 AAV9_PSyn::ATP1A3 Nov. 26, 2018 3-3 F Oct. 30, 2018 AAV9_PSyn::ATP1A3 Nov. 27, 2018 3-4 F Oct. 30, 2018 AAV9_PSyn::ATP1A3 Nov. 27, 2018 3-5 M Oct. 30, 2018 AAV9_PSyn::ATP1A3 Nov. 29, 2018 3-6 M Oct. 30, 2018 AAV9_PSyn::ATP1A3 Nov. 29, 2018 3-7 M Oct. 30, 2018 AAV9_PSyn::ATP1A3 Nov. 30, 2018 3-8 M Oct. 30, 2018 AAV9_PSyn::ATP1A3 Nov. 30, 2018 4-1 F Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 26, 2018 4-2 F Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 26, 2018 4-3 F Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 27, 2018 4-4 F Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 27, 2018 4-5 M Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 29, 2018 4-6 M Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 29, 2018 4-7 M Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 30, 2018 4-8 M Oct. 30, 2018 AAV9_PCBh::ATP1A3 Nov. 30, 2018 1. 8 brains (4m/4f) injected with AAV9_PATP1A3:: mCherry 2. 8 brains (4m/4f) injected with AAV9_PATP1A3:: ATP1A3 3. 8 brains (4m/4f) injected with AAV9_Psynapsin:: ATP1A3 4. 8 brains (4m/4f) injected with AAV9_PCBh::ATP1A3 - Brains received by Novaxia were pre-sliced to isolate the cerebellum, which was dehydrated and included in paraffin blocks. 4 μm slices were obtained from each cerebellum and put on glass slides.
- Fluofarma performed labelings, starting with multiple test conditions of multiple antibodies:
- Three ATP1A3 antibodies were tested, all from Rabbits:
-
- Sigma/Atlas antibody reference #HPA056446 at 1:1000
- EMD Millipore antibody reference #06-172-1 at 1:250
- ProteinTech antibody reference #10868-1-AP at 1:100
- One Calbindin antibody was tested (from chicken):
-
- Synaptic Systems reference #214006 at 1:200
- Three GAD67 antibodies were tested:
-
- Novusbio #NBP1-02161 at 1:1000 and 1:300
- Synaptic Systems #198 006 at 1:200
- Millipore #MAB5406 at 1:500
- One mCherry antibody was tested (from rat):
-
- Molecular Probes #M11217 at 1:200
- ATP1A3 antibodies were tested on hippocampal and cerebellum slices. The calbindin antibody was tested on cerebellum slices and the GAD67 antibody was tested on hippocampal slices.
- For each antibody, standard immunofluorescence protocols were performed using a Ventana XT automated platform, with two standard antigen retrieval procedures, at
pH 6 orpH 8 to determine the best antigen retrieval condition. - For ATP1A3, a secondary anti-rabbit Alexa 488 antibody was used for detection while for Calbindin and GAD67 and anti-chicken Alexa 594 antibody was used (Invitrogen, 1:400 dilution).
- For mCherry detection, as mCherry is a red fluorescent protein, an Alexa 594 anti-rat antibody was chosen for mCherry (1:400 dilution).
- Additional slides were labeled without the presence of primary antibody to control for potential background/aspecific stainings.
- For labeling mouse cerebella which were injected with AAV viruses, antigen retrieval was performed at pH8 for all antibodies, and slides were labeled with the anti-mCherry antibody (Molecular Probes #M11217) at 1:200+anti-Calbindin antibody (Synaptic Systems #214006) at 1:200, and anti-ATP1A3 antibody (EMD Millipore antibody #06-172-1) at 1:250+anti-Calbindin antibody (Synaptic Systems #214006) at 1:200.
- Secondary antibodies were Goat anti-rat Alexa 594 (Invitrogen #A11007)+Goat anti-Chicken Alexa 488 (Invitrogen #A11039) for mCherry/Calbindin and Goat anti-rabbit Alexa 488 (Invitrogen #A11008)+Goat anti-Chicken Alexa 594 (Invitrogen #A11042) for ATP1A3/Calbindin, all at 1:400 dilution.
- One slice per animal was stained.
- Staining involved the following categories of antibodies: ATP1A3 antibodies, Calbindin antibodies, GAD67 antibodies, and mCherry antibodies.
-
FIG. 1 depicts ATP1A3 (Millipore #06-172-1) staining in a mouse cerebellum. This ATP1A3 elicitates a good specific signal compared to the signal obtained in the absence of primary antibody, at both antigen retrieval pH. However, a higher signal was obtained with antigen retrieval at pH8. All images were acquired with the same microscope settings (exposure time, image dynamic range). -
FIG. 2 depicts ATP1A3 (Millipore #06-172-1) staining in mouse cerebellum. The zoomed image shows the ATP1A3 signal (green fluorescence channel) in the best condition, showing the widespread labeling and higher labeling fluorescence in what appears to be Purkinje cells. -
FIG. 3 depicts ATP1A3 (Millipore #06-172-1) staining in mouse brain at dorsal hippocampus level. This ATP1A3 antibody elicitates a good specific signal compared to the signal obtained in the absence of primary antibody, at both antigen retrieval pH. However, a higher signal was obtained with antigen retrieval at pH8. All images were acquired with the same microscope settings (exposure time, image dynamic range). -
FIG. 4 depicts ATP1A3 (Millipore #06-172-1) staining in mouse brain at dorsal hippocampus level. The zoomed image shows the ATP1A3 signal (green fluorescence channel) in the best condition, showing the widespread labeling. Some cells appear to have higher perinuclear signals in the parietal cortex and in the hippocampus in CA1, CA2-3 and Dentate Gyrus. -
FIG. 5 shows the ATP1A3 (Millipore #06-172-1) staining in the dorsal hippocampus. The zoomed image shows the ATP1A3 signal (green fluorescence channel) in the best condition (pH8 antigen retrieval) in the dorsal hippocampus. Arrows show cells with higher labeling. -
FIG. 6 shows the ATP1A3 (Millipore #06-172-1) staining in the parietal cortex. The zoomed image shows the ATP1A3 signal (green fluorescence channel) in the best condition (pH8 antigen retrieval), in the parietal cortex. Arrows show examples of cells with higher labeling. -
FIG. 7 depicts Calbindin (Synaptic Systems #214006) staining in mouse cerebellum. This antibody elicited the best specific signal over the negative control in the pH8 antigen retrieval condition. -
FIG. 8 depicts Calbindin (Synaptic Systems #214006) staining in mouse cerebellum. The zoomed image shows Purkinje cells labeled by the calbindin antibody using the pH8 antigen retrieval condition. -
FIG. 9 depicts GAD67 (Synaptic Systems #198 006) staining in mouse brain at dorsal hippocampus level. -
FIG. 10 depicts GAD67 (Synaptic Systems #198 006) staining in mouse brain at dorsal hippocampus level, pH8 antigen retrieval protocol. The zoomed image over the dorsal hippocampus (pH8 antigen retrieval protocol) shows the detection of GABAergic neurons with low fluorescence levels. -
FIG. 11 depicts GAD67 (Millipore #MAB5406) staining in mouse brain at dorsal hippocampus level. -
FIG. 12 depicts GAD67 (Millipore #MAB5406) staining in mouse brain at dorsal hippocampus level, pH8 antigen retrieval protocol. The zoomed image over the dorsal hippocampus (pH8 antigen retrieval protocol) shows good detection of GABAergic neurons in the hippocampus and in the cortex. - mCherry Antibody: Molecular Probes #M11217
-
FIG. 13 depicts mCherry staining in mouse cerebellum. Intense stainings are seen below the fourth ventricle and around this region. In the cerebellum, the staining is more diffuse, but specific staining is observed compared to negative brains (infected with ATP1A3 AAV viruses). -
FIG. 14 depicts the mouse cerebellum anatomy. VERM, indicating the Vermal regions, includes: LING Lingula (I); CENT Central lobule; CUL Culmen; DEC Declive (VI); FOTU Folium-tuber vermis (VII); PYR Pyramus (VIII); UVU Uvula (IX); and NOD Nodulus (X). HEM, indicating the Hemispheric regions, includes: SIM Simple lobule; AN Ansiform lobule; PRM Paramedian lobule; COPY Copula pyramidis; PFL Paraflocculus; and FL Flocculus. CBN, indicating Cerebellar nuclei, includes: FN Fastigial nucleus; IP Interposed nucleus; DN Dentate nucleus; and VeCB Vestibulocerebellar nucleus. -
FIG. 15 depicts mCherry staining in mouse cerebellum with pH8 antigen retrieval condition. The zoomed images are of the red channel. Intense stainings are seen below the fourth ventricle and around this region. In the cerebellum, the staining is more diffuse with occasionally a more intense cell that could be a Purkinje cell. -
FIG. 16 depicts mCherry staining in mouse cerebellum with pH8 antigen retrieval condition. The zoomed images are of the red channel at levels of Purkinje cell layers. Arrows show examples of Purkinje cells. - The Millipore #06-172-1 antibody demonstrated that it was able to detect the target protein, detecting a similar signal as disclosed in the Bottger et al. (2011) publication, in which the specificity of this antibody was shown.
- Calbindin was well detecting by the tested antibody, giving signals that can be segmented for Purkinje cell detection. The best condition was to use antigen retrieval at pH8.
- The GAD67 antibody from Synaptic Systems (#198 006) allowed detecting some GABAergic neurons but with low fluorescence levels over background.
- The GAD67 antibody from Millipore (#MAB5406) allowed detecting GABAergic neurons with good sensitivity and fluorescence levels and can thus be used for further steps of the study plan.
- The mCherry antibody allowed detecting positive cells only in the mCherry infected group, with strong signals below the fourth ventricle but also labelings in other regions. Co-labeling with the Calbindin antibody will allow determining if specific signals are measured in Purkinje cells. The signals in Purkinje cells are not as strong as below the fourth ventricle.
- ATP1A3 and Calbindin Staining in Cerebellum
- Calbindin signals allowed determining the localization of Purkinje neurons. In these, the ATP1A3 signals were peripheral to cells, so once cells were segmented, ATP1A3 was measured in a ring around the calbindin signal.
- Cell-by-cell data was fed into the proprietary Cytosurfer software to make cytometric analyses. The mean ATP1A3 fluorescence was plotted against cell count (
FIG. 17 ) and the cells from the same groups displayed group by group. The intensity histograms were well superposed. A gate was chosen to detect Purkinje cells with higher ATP1A3 intensity (FIG. 18 ) which should appear if ATP13 intensity is increased.FIGS. 19, 20, and 21 show the detected Purkinje neurons and the localization of cells with higher mean intensity. These cells are anatomically regularly spread and do not present a gradient from the cisterna magna. Moreover, inFIG. 21 , most of the cells detected with increased ATP1A3 are false positive due to creases in the cerebellum slice which induces a higher green fluorescence signal. - Quantification of ATP1A3 in the different experimental groups shows that the use of ATP1A3 expressing AAV viruses did not increase ATP1A3 mean fluorescence in Purkinje neurons, nor the percentage of cells with increased ATP1A3 expression (
FIG. 22 ). Similarly, no differences appeared in other cells that were analyzed (FIG. 23 ). - mCherry and Calbindin Staining in Cerebellum
- mCherry expression was used as a positive control of AAV injection and transgene expression. Cytometric analysis of mCherry intensity in Purkinje neurons showed a similar profile in mCherry infected mice compared to ATP1A3 infected mice (
FIG. 24 ). A few cells with higher mCherry fluorescence were detected, but this was artificial as these higher signals appeared where creases in the tissue were present (FIG. 25 ). Quantifications support the absence of differences between treatment groups in Purkinje Neurons (FIG. 26 ) and other cells (FIG. 27 ). - mCherry Staining in Brainstem
- Depending on the slices, the brainstem was more or less preserved. mCherry staining was well detected in some brainstems of mCherry-AAV infected brains while no specific signals were present in ATP1A3-AAV infected brains. The pattern of mCherry expression was not widespread but instead focalized in discrete regions, which suggests that the injection site was not truly in the Cisterna Magna but rather in the brainstem itself. Moreover, in some brainstems, no mCherry expression could be detected (
FIG. 28 ). - ATP1A3 Staining in Brainstem
- Contrary to mCherry, there were no obvious localization of higher ATP1A3 signals in the brainstem. A few cells showed higher intensity but were spread in the brainstem. The staining intensity in general and staining intensity in highest intensity cells were not different for the different experimental groups and compared to the mCherry-infected group (
FIG. 29 ). The interimage variability was higher than the intra image variability and quantifications do not show clear cut differences between ATP1A3 expressing AAV viruses (FIG. 30 ). -
-
Percentage Purkinje neurons with High ATP1A3 AAV9_ AAV9_ AAV9_ AAV9_ PAT P1A3:: PAT P1A3:: Psynapsin:: PCBh:: mCherry ATP1A3 ATP1A3 ATP1A3 9.08 0.534 8.91 13.3 0.957 0.212 0 2.4 1.19 9.57 10.6 0.742 0.668 1.39 5.05 1.52 0.838 3.56 1.77 0.775 0.175 1.72 0.114 0.644 2.21 14.4 1.86 0.204 9.08 1.36 0.629 11.9 -
Mean ATP1A3 fluorescence in Purkinje Neurons AAV9_ AAV9_ AAV9_ AAV9_ PAT P1A3:: PAT P1A3:: Psynapsin:: PCBh:: mCherry ATP1A3 ATP1A3 ATP1A3 99.8 76.2 89.9 98.7 74.4 73.9 67.8 86.4 76.7 96 85.4 81.5 75.9 82 78.3 82.1 70.3 88 87.1 75.3 75.2 86.1 71.2 81.5 85.2 100 84.4 71 97.9 86.8 72.3 102 -
Mean ATP1A3 fluorescence in other cells AAV9_ AAV9_ AAV9_ AAV9_ PAT P1A3:: PAT P1A3:: Psynapsin:: PCBh:: mCherry ATP1A3 ATP1A3 ATP1A3 80.7 43.7 58.2 71.6 38.6 38.9 22.5 64.7 42.9 74.6 47.1 55.9 40.3 55.2 40.4 56.9 27.8 67.4 66.8 37.3 41.1 62.2 26.6 58.6 66.3 70.2 59.6 26.7 75.5 67.5 30.6 81.7 -
Percentage Purkinje neurons with High mCherry AAV9_PAT ATP1A3 P1A3:: infected mCherry brains 2.14 0.358 2.08 5.27 1.93 2.43 0.303 3.66 0 1.44 1.44 0.149 1.11 0.366 -
Mean mCherry fluorescence in Purkinje Neurons AAV9_PAT ATP1A3 P1A3:: infected mCherry brains 16.3 13.5 13.4 19 15.1 18.6 13.8 17.1 14 14.5 13.4 12.7 13 13.2 -
Mean mCherry fluorescence in other cells AAV9_PAT ATP1A3 P1A3:: infected mCherry brains 127 98.6 123 132 93.9 106 164 118 113 90.2 93.3 86.9 149 123 -
-
Number of mCherry positive cells in brainstem ATP1A3 mCherry mCherry infected infected infected brains brains brains, no Ab 1 9 0 1 74 0 21 26 0 1 16 0 6 4 0 4 29 3 0 0 0 0 -
Mean ATP1A3 fluorescence in all cells AAV9_PAT AAV9_PAT AAV9_ AAV9 P1A3:: P1A3:: Psynapsin:: PCBh:: mCherry ATP1A3 ATP1A3 ATP1A3 0.9594657 1.5719883 1.6757175 1.2800999 1.2781088 1.3089229 1.0601813 1.5957804 1.3683764 1.9546749 1.2545795 1.3809592 1.7401803 1.2677235 1.3345006 1.0735391 0.9455498 1.3787239 1.2546315 1.1570685 1.7301957 1.3529171 1.3236297 1.4783155 1.3649146 1.0431079 1.2071395 1.192403 1.6091142 0.919077 1.1412062 1.3906967 -
Percentage of cells with higher ATP1A3 expression AAV9_PAT AAV9_PAT AAV9_ AAV9 P1A3:: P1A3:: Psynapsin:: PCBh:: mCherry ATP1A3 ATP1A3 ATP1A3 0 0.0141583 0.0179856 22.941409 13.759039 14.096621 25.746196 0.0182615 0.0386548 0 21.581866 13.021047 0.066357 28.1575 13.068149 26.281911 0.0786164 31.462178 29.967949 25.172961 0 0 14.827064 0.067128 0 28.490776 28.233045 21.261966 0 0 28.181818 15.526353 -
ATP1A3 mean fluorescence in subpopulation with higher ATP1A3 AAV9_PAT AAV9_PAT AAV9_ AAV9 P1A3:: P1A3:: Psynapsin:: PCBh:: mCherry ATP1A3 ATP1A3 ATP1A3 0 12 12 6.579797 5.997402 5.9995585 7.1953383 8.75 5.848485 0 6.5679874 6.0148131 8.8166668 7.1851386 6.0072859 7.1872419 10 7.1648367 7.183503 7.1800464 0 0 6.0020599 6.1937063 0 8.5209115 7.1846988 6.5676226 0 0 7.177844 6.0161244
Claims (15)
1. A method for treating a subject having alternating hemiplegia of childhood (AHC), the method comprising:
administering into the central nervous system (CNS) of the subject a recombinant adeno-associated virus (AAV) vector composition comprising a nucleic acid sequence encoding a ATP1A3 protein, and a promoter sequence that renders the expression of the ATP1A3 protein-coding nucleic acid sequence specific to the central nervous system; wherein the AAV vector is AAV9, and wherein the promoter is a human neuron-specific promoter with a strong bias towards inhibitory neuron (PhSyn),
thereby restoring some degree of neurological function in said subject.
2. The method of claim 1 , wherein the recombinant AAV vector is administered to one or more CNS components selected from the group consisting of cerebrospinal fluid (CSF), cisterna magna (cerebellomedullaris cistern), cerebral ventricles, the spinal cord, brainstem, hippocampus, cerebellum, cerebral cortex, diencephalon, and telencephalon.
3. The method of claim 1 , wherein the administration is via intracisternal, intrathecal, or intracerebroventricular injection.
4. The method of claim 1 , wherein the subject is human.
5. The method of claim 1 , wherein the recombinant AAV vector composition further comprising one or more nucleic acid regulatory sequences, linked directly or indirectly to the ATP1A3 protein-coding nucleic acid sequence.
6. The method of claim 5 , wherein the nucleic acid regulatory sequence comprises a sequence to regulate ribosome binding and/or translation efficiency of the ATP1A3 gene.
7. The method of claim 6 , wherein the sequence to regulate ribosome binding and/or translation efficiency is a Kozak sequence.
8. The method of claim 5 , wherein the nucleic acid regulatory sequence comprises a 3′-UTR sequence that contains a polyadenylation signal sequence.
9. The method of claim 8 , wherein the 3′-UTR sequence is a rabbit beta globin polyadenylation signal sequence (rBGpA).
10. The method of claim 5 , wherein the recombinant AAV vector comprises AAV9/PhSyn-ATP1A3 cDNA-rBGpA.
11. The method of claim 1 , wherein the AAV9 vector has a single-stranded DNA genome.
12. The method of claim 1 , wherein the recombinant AAV vector comprises SEQ ID NO: 3.
13. The method of claim 1 , wherein the recombinant AAV vector comprises SEQ ID NO: 4.
14. The method of claim 1 , wherein the recombinant AAV vector comprises SEQ ID NO: 5.
15. The method of claim 1 , wherein the recombinant AAV vector comprises SEQ ID NO: 6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/449,346 US20230381340A1 (en) | 2018-04-09 | 2023-08-14 | Aav-mediated delivery of atp1a3 genes to central nervous system |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862654645P | 2018-04-09 | 2018-04-09 | |
US16/379,440 US11738093B2 (en) | 2018-04-09 | 2019-04-09 | AAV-mediated delivery of ATP1A3 genes to central nervous system |
US18/449,346 US20230381340A1 (en) | 2018-04-09 | 2023-08-14 | Aav-mediated delivery of atp1a3 genes to central nervous system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/379,440 Continuation US11738093B2 (en) | 2018-04-09 | 2019-04-09 | AAV-mediated delivery of ATP1A3 genes to central nervous system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230381340A1 true US20230381340A1 (en) | 2023-11-30 |
Family
ID=68163293
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/379,440 Active 2040-12-06 US11738093B2 (en) | 2018-04-09 | 2019-04-09 | AAV-mediated delivery of ATP1A3 genes to central nervous system |
US18/449,346 Pending US20230381340A1 (en) | 2018-04-09 | 2023-08-14 | Aav-mediated delivery of atp1a3 genes to central nervous system |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/379,440 Active 2040-12-06 US11738093B2 (en) | 2018-04-09 | 2019-04-09 | AAV-mediated delivery of ATP1A3 genes to central nervous system |
Country Status (2)
Country | Link |
---|---|
US (2) | US11738093B2 (en) |
WO (1) | WO2019199841A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114072514A (en) | 2019-05-14 | 2022-02-18 | 杜克大学 | Compositions and methods for treating ATPase mediated diseases |
GB202001930D0 (en) * | 2020-02-12 | 2020-03-25 | Univ Sheffield | Gene therapy |
EP4281034A1 (en) | 2021-01-24 | 2023-11-29 | Forrest, Michael, David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
CN113652427B (en) * | 2021-08-20 | 2023-08-29 | 深圳市恩辑生物科技有限公司 | Mini promoter pATP1B1 and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012115980A1 (en) * | 2011-02-22 | 2012-08-30 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (aav) vectors |
JP6415977B2 (en) * | 2011-04-15 | 2018-10-31 | ジェネラックス・コーポレイションGenelux Corporation | Cloned strain of attenuated vaccinia virus and method of using the same |
KR20220082100A (en) * | 2015-05-15 | 2022-06-16 | 리젠츠 오브 더 유니버시티 오브 미네소타 | Adeno-associated for therapeutic delivery to central nervous system |
-
2019
- 2019-04-09 WO PCT/US2019/026602 patent/WO2019199841A1/en active Application Filing
- 2019-04-09 US US16/379,440 patent/US11738093B2/en active Active
-
2023
- 2023-08-14 US US18/449,346 patent/US20230381340A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11738093B2 (en) | 2023-08-29 |
US20190358346A1 (en) | 2019-11-28 |
WO2019199841A1 (en) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230381340A1 (en) | Aav-mediated delivery of atp1a3 genes to central nervous system | |
US11975043B2 (en) | Gene therapy for neurodegenerative disorders | |
US20210115473A1 (en) | METHOD FOR TRANSDUCING Title of Invention CELLS WITH PRIMARY CILIA | |
JP2020050660A (en) | Gene therapy for spinal cord disorders | |
EP2121914B1 (en) | Mitochondrial nucleic acid delivery systems | |
CN105408352A (en) | Effective delivery of large genes by dual aav vectors | |
KR20200116550A (en) | Capsid-free aav vectors, compositions, and methods for vector production and gene delivery | |
JP7231922B2 (en) | AAV-IDUA vectors for the treatment of MPS-I-associated blindness | |
US20190002916A1 (en) | Hybrid dual recombinant aav vector systems for gene therapy | |
US11680276B2 (en) | Compositions and methods for treating retinal disorders | |
KR20210049131A (en) | Gene Sequence of Recombinant Human Type II Mitochondrial Dynein-Like GTPase and Use thereof | |
CN108103096A (en) | A kind of Xian Xing Before-daybreak diseases gene therapy medicament | |
US20200261600A1 (en) | Method for the treatment or prevention of pain or excessive neuronal activity or epilepsy | |
US20230227515A1 (en) | Optimized gene therapy for targeting muscle in muscle diseases | |
EP4017871A1 (en) | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy | |
US20240067989A1 (en) | Compositions and Methods for Treating Retinal Disorders | |
US11357870B2 (en) | Codon optimized REP1 genes and uses thereof | |
US20230149564A1 (en) | Aav-naglu vectors for treatment of mucopolysaccharidosis iiib | |
WO2024011109A2 (en) | Compositions and methods for treatment of achromotopsia | |
WO2024033837A1 (en) | Human cone photoreceptor optogenetic constructs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |